CA2836085A1 - 2-benzylidene-2h-benzo[b][1,4] thiazin-3(4h)-ones substituees, derives et usage therapeutique de celles-ci - Google Patents

2-benzylidene-2h-benzo[b][1,4] thiazin-3(4h)-ones substituees, derives et usage therapeutique de celles-ci Download PDF

Info

Publication number: CA2836085A1
Authority: CA; Canada
Prior art keywords: benzo; thiazin; sulfonyl; methyl; dihydro
Prior art date: 2013-12-05
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA2836085A

Other languages

English (en)

Inventor

E. Premkumar Reddy

M. V. Ramana Reddy

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Icahn School of Medicine at Mount Sinai

Temple Univ School of Medicine

Original Assignee

Icahn School of Medicine at Mount Sinai

Temple Univ School of Medicine

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-12-05

Filing date

2013-12-05

Publication date

2015-06-05

2013-12-05 Application filed by Icahn School of Medicine at Mount Sinai, Temple Univ School of Medicine filed Critical Icahn School of Medicine at Mount Sinai

2013-12-05 Priority to CA2836085A priority Critical patent/CA2836085A1/fr

2015-06-05 Publication of CA2836085A1 publication Critical patent/CA2836085A1/fr

Status Abandoned legal-status Critical Current

Links

230000001225 therapeutic effect Effects 0.000 title description 6
DOQUSBFMNDTPGT-UHFFFAOYSA-N 2-benzylidene-4h-1,4-benzothiazin-3-one Chemical class O=C1NC2=CC=CC=C2SC1=CC1=CC=CC=C1 DOQUSBFMNDTPGT-UHFFFAOYSA-N 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 268
206010028980 Neoplasm Diseases 0.000 claims abstract description 100
150000003839 salts Chemical class 0.000 claims abstract description 96
238000000034 method Methods 0.000 claims abstract description 65
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 60
201000011510 cancer Diseases 0.000 claims abstract description 53
230000002062 proliferating effect Effects 0.000 claims abstract description 48
230000001413 cellular effect Effects 0.000 claims abstract description 39
-1 2,3-dichlorophenyl Chemical group 0.000 claims description 375
125000000217 alkyl group Chemical group 0.000 claims description 67
GTFMIJNXNMDHAB-UHFFFAOYSA-N 4h-1,4-benzothiazin-3-one Chemical compound C1=CC=C2NC(=O)CSC2=C1 GTFMIJNXNMDHAB-UHFFFAOYSA-N 0.000 claims description 63
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 58
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 55
208000035475 disorder Diseases 0.000 claims description 53
125000001072 heteroaryl group Chemical group 0.000 claims description 51
210000004027 cell Anatomy 0.000 claims description 49
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 36
102000052052 Casein Kinase II Human genes 0.000 claims description 32
108010010919 Casein Kinase II Proteins 0.000 claims description 32
125000003107 substituted aryl group Chemical group 0.000 claims description 31
229910052739 hydrogen Inorganic materials 0.000 claims description 29
125000000623 heterocyclic group Chemical group 0.000 claims description 28
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical group CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 27
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 26
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 24
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 23
229910052736 halogen Inorganic materials 0.000 claims description 22
150000002367 halogens Chemical class 0.000 claims description 22
229940127121 immunoconjugate Drugs 0.000 claims description 22
230000000694 effects Effects 0.000 claims description 21
229910052757 nitrogen Inorganic materials 0.000 claims description 20
108010025461 Cyclin-Dependent Kinase 9 Proteins 0.000 claims description 19
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 18
125000003118 aryl group Chemical group 0.000 claims description 18
239000001257 hydrogen Substances 0.000 claims description 18
210000004881 tumor cell Anatomy 0.000 claims description 16
108091000080 Phosphotransferase Proteins 0.000 claims description 15
102000020233 phosphotransferase Human genes 0.000 claims description 15
239000011541 reaction mixture Substances 0.000 claims description 15
229920001774 Perfluoroether Polymers 0.000 claims description 14
206010060862 Prostate cancer Diseases 0.000 claims description 14
208000000236 Prostatic Neoplasms Diseases 0.000 claims description 14
230000008569 process Effects 0.000 claims description 14
206010006187 Breast cancer Diseases 0.000 claims description 13
208000026310 Breast neoplasm Diseases 0.000 claims description 13
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 12
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical group CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 12
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 12
125000001424 substituent group Chemical group 0.000 claims description 12
230000006907 apoptotic process Effects 0.000 claims description 11
239000008194 pharmaceutical composition Substances 0.000 claims description 11
101001064870 Homo sapiens Lon protease homolog, mitochondrial Proteins 0.000 claims description 10
101000595531 Homo sapiens Serine/threonine-protein kinase pim-1 Proteins 0.000 claims description 10
102100031955 Lon protease homolog, mitochondrial Human genes 0.000 claims description 10
125000004093 cyano group Chemical group *C#N 0.000 claims description 10
239000003937 drug carrier Substances 0.000 claims description 10
125000005647 linker group Chemical group 0.000 claims description 10
150000008064 anhydrides Chemical class 0.000 claims description 9
208000032839 leukemia Diseases 0.000 claims description 9
230000001939 inductive effect Effects 0.000 claims description 8
208000020816 lung neoplasm Diseases 0.000 claims description 7
125000006693 (C2-C9) heterocyclyl group Chemical group 0.000 claims description 6
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 6
208000003174 Brain Neoplasms Diseases 0.000 claims description 6
208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 6
206010009944 Colon cancer Diseases 0.000 claims description 6
208000001333 Colorectal Neoplasms Diseases 0.000 claims description 6
208000008839 Kidney Neoplasms Diseases 0.000 claims description 6
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 6
206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
208000000453 Skin Neoplasms Diseases 0.000 claims description 6
208000024313 Testicular Neoplasms Diseases 0.000 claims description 6
201000010099 disease Diseases 0.000 claims description 6
201000010260 leiomyoma Diseases 0.000 claims description 6
KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 claims description 5
FEXJVEZCIWUQMB-UHFFFAOYSA-N 3-oxo-4h-1,4-benzothiazine-6-sulfonyl chloride Chemical compound S1CC(=O)NC2=CC(S(=O)(=O)Cl)=CC=C21 FEXJVEZCIWUQMB-UHFFFAOYSA-N 0.000 claims description 5
208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 5
208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 5
206010033128 Ovarian cancer Diseases 0.000 claims description 5
208000016738 bone Paget disease Diseases 0.000 claims description 5
XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 claims description 5
125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
238000010992 reflux Methods 0.000 claims description 5
201000003120 testicular cancer Diseases 0.000 claims description 5
208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 4
208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 4
208000001708 Dupuytren contracture Diseases 0.000 claims description 4
206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
208000009905 Neurofibromatoses Diseases 0.000 claims description 4
208000004362 Penile Induration Diseases 0.000 claims description 4
208000020758 Peyronie disease Diseases 0.000 claims description 4
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 4
208000002158 Proliferative Vitreoretinopathy Diseases 0.000 claims description 4
206010038389 Renal cancer Diseases 0.000 claims description 4
206010038934 Retinopathy proliferative Diseases 0.000 claims description 4
206010046798 Uterine leiomyoma Diseases 0.000 claims description 4
208000011803 breast fibrocystic disease Diseases 0.000 claims description 4
230000001684 chronic effect Effects 0.000 claims description 4
208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 4
208000007118 chronic progressive multiple sclerosis Diseases 0.000 claims description 4
208000011379 keloid formation Diseases 0.000 claims description 4
201000010982 kidney cancer Diseases 0.000 claims description 4
201000005202 lung cancer Diseases 0.000 claims description 4
208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 claims description 4
201000004931 neurofibromatosis Diseases 0.000 claims description 4
230000000750 progressive effect Effects 0.000 claims description 4
230000006785 proliferative vitreoretinopathy Effects 0.000 claims description 4
210000002307 prostate Anatomy 0.000 claims description 4
208000037803 restenosis Diseases 0.000 claims description 4
201000008628 secondary progressive multiple sclerosis Diseases 0.000 claims description 4
JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 claims description 4
GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 4
201000001320 Atherosclerosis Diseases 0.000 claims description 3
206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 3
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 3
206010008342 Cervix carcinoma Diseases 0.000 claims description 3
229940126062 Compound A Drugs 0.000 claims description 3
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 3
208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 3
206010038923 Retinopathy Diseases 0.000 claims description 3
206010057644 Testis cancer Diseases 0.000 claims description 3
208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
210000000481 breast Anatomy 0.000 claims description 3
201000010881 cervical cancer Diseases 0.000 claims description 3
208000002780 macular degeneration Diseases 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 3
208000035803 proliferative type breast fibrocystic change Diseases 0.000 claims description 3
201000000849 skin cancer Diseases 0.000 claims description 3
238000002054 transplantation Methods 0.000 claims description 3
KSLTWQNPEKSZLJ-NHDPSOOVSA-N (2z)-7-fluoro-2-[(3-nitro-4-phenylmethoxyphenyl)methylidene]-4h-1,4-benzothiazin-3-one Chemical compound [O-][N+](=O)C1=CC(\C=C/2C(NC3=CC=C(F)C=C3S\2)=O)=CC=C1OCC1=CC=CC=C1 KSLTWQNPEKSZLJ-NHDPSOOVSA-N 0.000 claims description 2
QBDUZEZPLCWJRZ-NSIKDUERSA-N (2z)-7-fluoro-2-[(4-hydroxy-3-nitrophenyl)methylidene]-4h-1,4-benzothiazin-3-one Chemical compound C1=C([N+]([O-])=O)C(O)=CC=C1\C=C/1C(=O)NC2=CC=C(F)C=C2S\1 QBDUZEZPLCWJRZ-NSIKDUERSA-N 0.000 claims description 2
125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims description 2
125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims description 2
125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims description 2
206010029098 Neoplasm skin Diseases 0.000 claims description 2
SRCDLPVCGIWRAS-APSNUPSMSA-N [4-[(z)-(6-chloro-3-oxo-4h-1,4-benzothiazin-2-ylidene)methyl]-2-nitrophenyl] acetate Chemical compound C1=C([N+]([O-])=O)C(OC(=O)C)=CC=C1\C=C/1C(=O)NC2=CC(Cl)=CC=C2S\1 SRCDLPVCGIWRAS-APSNUPSMSA-N 0.000 claims description 2
DLJNMQVFIVXDJY-APSNUPSMSA-N [4-[(z)-(7-bromo-3-oxo-4h-1,4-benzothiazin-2-ylidene)methyl]-2-nitrophenyl] acetate Chemical compound C1=C([N+]([O-])=O)C(OC(=O)C)=CC=C1\C=C/1C(=O)NC2=CC=C(Br)C=C2S\1 DLJNMQVFIVXDJY-APSNUPSMSA-N 0.000 claims description 2
LNOQNHNJELOZGN-IUXPMGMMSA-N [4-[(z)-(7-methoxy-3-oxo-4h-1,4-benzothiazin-2-ylidene)methyl]-2-nitrophenyl] acetate Chemical compound S1C2=CC(OC)=CC=C2NC(=O)\C1=C\C1=CC=C(OC(C)=O)C([N+]([O-])=O)=C1 LNOQNHNJELOZGN-IUXPMGMMSA-N 0.000 claims description 2
238000009833 condensation Methods 0.000 claims description 2
230000005494 condensation Effects 0.000 claims description 2
210000004072 lung Anatomy 0.000 claims description 2
208000037841 lung tumor Diseases 0.000 claims description 2
208000025189 neoplasm of testis Diseases 0.000 claims description 2
230000002611 ovarian Effects 0.000 claims description 2
208000023958 prostate neoplasm Diseases 0.000 claims description 2
235000010265 sodium sulphite Nutrition 0.000 claims description 2
230000002381 testicular Effects 0.000 claims description 2
208000024719 uterine cervix neoplasm Diseases 0.000 claims description 2
DOMBZVXKSRQDOJ-NKVSQWTQSA-N (2z)-6-[(2,6-dichlorophenyl)methylsulfonyl]-2-[(4-hydroxy-3-nitrophenyl)methylidene]-4h-1,4-benzothiazin-3-one Chemical compound C1=C([N+]([O-])=O)C(O)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3Cl)Cl)=CC=C2S\1 DOMBZVXKSRQDOJ-NKVSQWTQSA-N 0.000 claims 3
AROLLVJZWKGOFL-WNFQYIGGSA-N (2z)-2-[(2,4-difluorophenyl)methylidene]-6-[(2,6-difluorophenyl)methylsulfonyl]-4h-1,4-benzothiazin-3-one Chemical compound FC1=CC(F)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3F)F)=CC=C2S\1 AROLLVJZWKGOFL-WNFQYIGGSA-N 0.000 claims 2
AZDRAOIRAOZEHE-NKVSQWTQSA-N (2z)-6-[(2,6-dibromophenyl)methylsulfonyl]-2-[(2,4,6-trifluorophenyl)methylidene]-4h-1,4-benzothiazin-3-one Chemical compound FC1=CC(F)=CC(F)=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3Br)Br)=CC=C2S\1 AZDRAOIRAOZEHE-NKVSQWTQSA-N 0.000 claims 2
FHONDLDVBIZKPC-NKVSQWTQSA-N (2z)-6-[(2,6-dichlorophenyl)methylsulfonyl]-2-[(2,4,6-trifluorophenyl)methylidene]-4h-1,4-benzothiazin-3-one Chemical compound FC1=CC(F)=CC(F)=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3Cl)Cl)=CC=C2S\1 FHONDLDVBIZKPC-NKVSQWTQSA-N 0.000 claims 2
HHAXXQFZPIVEAA-KSEXSDGBSA-N (2z)-6-[(2,6-dimethoxyphenyl)methylsulfonyl]-2-[(2,4,6-trifluorophenyl)methylidene]-4h-1,4-benzothiazin-3-one Chemical compound COC1=CC=CC(OC)=C1CS(=O)(=O)C1=CC=C(S\C(=C/C=2C(=CC(F)=CC=2F)F)C(=O)N2)C2=C1 HHAXXQFZPIVEAA-KSEXSDGBSA-N 0.000 claims 2
KXWWZOFLNMALHY-KSEXSDGBSA-N (2z)-6-[(2,6-dimethylphenyl)methylsulfonyl]-2-[(2,4,6-trifluorophenyl)methylidene]-4h-1,4-benzothiazin-3-one Chemical compound CC1=CC=CC(C)=C1CS(=O)(=O)C1=CC=C(S\C(=C/C=2C(=CC(F)=CC=2F)F)C(=O)N2)C2=C1 KXWWZOFLNMALHY-KSEXSDGBSA-N 0.000 claims 2
102100024457 Cyclin-dependent kinase 9 Human genes 0.000 claims 2
239000012048 reactive intermediate Substances 0.000 claims 2
DQSNOMCXASNIQT-GATIEOLUSA-N (2z)-2-[(1-acetylindol-3-yl)methylidene]-6-[(2,6-dichlorophenyl)methylsulfonyl]-4h-1,4-benzothiazin-3-one Chemical compound C12=CC=CC=C2N(C(=O)C)C=C1\C=C(C(NC1=C2)=O)/SC1=CC=C2S(=O)(=O)CC1=C(Cl)C=CC=C1Cl DQSNOMCXASNIQT-GATIEOLUSA-N 0.000 claims 1
JPLHTNNPNLUPMI-WNFQYIGGSA-N (2z)-2-[(2,4-dibromophenyl)methylidene]-6-[(2,6-dibromophenyl)methylsulfonyl]-4h-1,4-benzothiazin-3-one Chemical compound BrC1=CC(Br)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3Br)Br)=CC=C2S\1 JPLHTNNPNLUPMI-WNFQYIGGSA-N 0.000 claims 1
PJBQRRYGKBSWEC-WNFQYIGGSA-N (2z)-2-[(2,4-dichlorophenyl)methylidene]-6-[(2,6-dichlorophenyl)methylsulfonyl]-4h-1,4-benzothiazin-3-one Chemical compound ClC1=CC(Cl)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3Cl)Cl)=CC=C2S\1 PJBQRRYGKBSWEC-WNFQYIGGSA-N 0.000 claims 1
BZMLIUFGFVWVOV-RMORIDSASA-N (2z)-2-[(2,4-difluorophenyl)methylidene]-6-[(2,6-dimethylphenyl)methylsulfonyl]-4h-1,4-benzothiazin-3-one Chemical compound CC1=CC=CC(C)=C1CS(=O)(=O)C1=CC=C(S\C(=C/C=2C(=CC(F)=CC=2)F)C(=O)N2)C2=C1 BZMLIUFGFVWVOV-RMORIDSASA-N 0.000 claims 1
WFIRNOYGDPFYPV-YVNNLAQVSA-N (2z)-2-[(3-amino-4-methoxyphenyl)methylidene]-6-[(2,6-dibromophenyl)methylsulfonyl]-4h-1,4-benzothiazin-3-one Chemical compound C1=C(N)C(OC)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3Br)Br)=CC=C2S\1 WFIRNOYGDPFYPV-YVNNLAQVSA-N 0.000 claims 1
DPQIGPDRSOSGMI-YVNNLAQVSA-N (2z)-2-[(3-amino-4-methoxyphenyl)methylidene]-6-[(2,6-dichlorophenyl)methylsulfonyl]-4h-1,4-benzothiazin-3-one Chemical compound C1=C(N)C(OC)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3Cl)Cl)=CC=C2S\1 DPQIGPDRSOSGMI-YVNNLAQVSA-N 0.000 claims 1
QVIFGVSEDLBODR-YVNNLAQVSA-N (2z)-2-[(3-amino-4-methoxyphenyl)methylidene]-6-[(2,6-difluorophenyl)methylsulfonyl]-4h-1,4-benzothiazin-3-one Chemical compound C1=C(N)C(OC)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3F)F)=CC=C2S\1 QVIFGVSEDLBODR-YVNNLAQVSA-N 0.000 claims 1
BVWAAHBOPSRIFJ-MSXFZWOLSA-N (2z)-2-[(3-amino-4-methoxyphenyl)methylidene]-6-[(2,6-dimethoxyphenyl)methylsulfonyl]-4h-1,4-benzothiazin-3-one Chemical compound C1=C(N)C(OC)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3OC)OC)=CC=C2S\1 BVWAAHBOPSRIFJ-MSXFZWOLSA-N 0.000 claims 1
VTCXDYNACWXVRE-MSXFZWOLSA-N (2z)-2-[(3-amino-4-methoxyphenyl)methylidene]-6-[(2,6-dimethylphenyl)methylsulfonyl]-4h-1,4-benzothiazin-3-one Chemical compound C1=C(N)C(OC)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3C)C)=CC=C2S\1 VTCXDYNACWXVRE-MSXFZWOLSA-N 0.000 claims 1
BJPVWJWJEBJQBH-APSNUPSMSA-N (2z)-2-[(4-acetyloxy-3-nitrophenyl)methylidene]-3-oxo-4h-1,4-benzothiazine-7-carboxylic acid Chemical compound C1=C([N+]([O-])=O)C(OC(=O)C)=CC=C1\C=C/1C(=O)NC2=CC=C(C(O)=O)C=C2S\1 BJPVWJWJEBJQBH-APSNUPSMSA-N 0.000 claims 1
VZYCTJNPSGQLBN-FBHDLOMBSA-N (2z)-2-[(4-aminophenyl)methylidene]-6-[(2,6-dibromophenyl)methylsulfonyl]-4h-1,4-benzothiazin-3-one Chemical compound C1=CC(N)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3Br)Br)=CC=C2S\1 VZYCTJNPSGQLBN-FBHDLOMBSA-N 0.000 claims 1
JISPXZHLGWDYBC-FBHDLOMBSA-N (2z)-2-[(4-aminophenyl)methylidene]-6-[(2,6-dichlorophenyl)methylsulfonyl]-4h-1,4-benzothiazin-3-one Chemical compound C1=CC(N)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3Cl)Cl)=CC=C2S\1 JISPXZHLGWDYBC-FBHDLOMBSA-N 0.000 claims 1
BTZDCNRTKUGZNU-FBHDLOMBSA-N (2z)-2-[(4-aminophenyl)methylidene]-6-[(2,6-difluorophenyl)methylsulfonyl]-4h-1,4-benzothiazin-3-one Chemical compound C1=CC(N)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3F)F)=CC=C2S\1 BTZDCNRTKUGZNU-FBHDLOMBSA-N 0.000 claims 1
HVDUECLGWYAMBI-FMCGGJTJSA-N (2z)-2-[(4-aminophenyl)methylidene]-6-[(2,6-dimethylphenyl)methylsulfonyl]-4h-1,4-benzothiazin-3-one Chemical compound CC1=CC=CC(C)=C1CS(=O)(=O)C1=CC=C(S\C(=C/C=2C=CC(N)=CC=2)C(=O)N2)C2=C1 HVDUECLGWYAMBI-FMCGGJTJSA-N 0.000 claims 1
ZAIZNIQJNYKZLF-FBHDLOMBSA-N (2z)-2-[(4-bromophenyl)methylidene]-6-[(2,6-dibromophenyl)methylsulfonyl]-4h-1,4-benzothiazin-3-one Chemical compound C1=CC(Br)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3Br)Br)=CC=C2S\1 ZAIZNIQJNYKZLF-FBHDLOMBSA-N 0.000 claims 1
KRVXYWUZOQQMGH-FBHDLOMBSA-N (2z)-2-[(4-bromophenyl)methylidene]-6-[(2,6-dichlorophenyl)methylsulfonyl]-4h-1,4-benzothiazin-3-one Chemical compound ClC1=CC=CC(Cl)=C1CS(=O)(=O)C1=CC=C(S\C(=C/C=2C=CC(Br)=CC=2)C(=O)N2)C2=C1 KRVXYWUZOQQMGH-FBHDLOMBSA-N 0.000 claims 1
IREXRTCOIXJPMY-FBHDLOMBSA-N (2z)-2-[(4-bromophenyl)methylidene]-6-[(2,6-difluorophenyl)methylsulfonyl]-4h-1,4-benzothiazin-3-one Chemical compound FC1=CC=CC(F)=C1CS(=O)(=O)C1=CC=C(S\C(=C/C=2C=CC(Br)=CC=2)C(=O)N2)C2=C1 IREXRTCOIXJPMY-FBHDLOMBSA-N 0.000 claims 1
BUWKGXWJPQHMIX-FMCGGJTJSA-N (2z)-2-[(4-bromophenyl)methylidene]-6-[(2,6-dimethoxyphenyl)methylsulfonyl]-4h-1,4-benzothiazin-3-one Chemical compound COC1=CC=CC(OC)=C1CS(=O)(=O)C1=CC=C(S\C(=C/C=2C=CC(Br)=CC=2)C(=O)N2)C2=C1 BUWKGXWJPQHMIX-FMCGGJTJSA-N 0.000 claims 1
HZYDRLZNSJUHAY-FMCGGJTJSA-N (2z)-2-[(4-bromophenyl)methylidene]-6-[(2,6-dimethylphenyl)methylsulfonyl]-4h-1,4-benzothiazin-3-one Chemical compound CC1=CC=CC(C)=C1CS(=O)(=O)C1=CC=C(S\C(=C/C=2C=CC(Br)=CC=2)C(=O)N2)C2=C1 HZYDRLZNSJUHAY-FMCGGJTJSA-N 0.000 claims 1
VLBVIUNMMBRYFR-NKVSQWTQSA-N (2z)-2-[(4-chloro-3-nitrophenyl)methylidene]-6-[(2,6-dibromophenyl)methylsulfonyl]-4h-1,4-benzothiazin-3-one Chemical compound C1=C(Cl)C([N+](=O)[O-])=CC(\C=C/2C(NC3=CC(=CC=C3S\2)S(=O)(=O)CC=2C(=CC=CC=2Br)Br)=O)=C1 VLBVIUNMMBRYFR-NKVSQWTQSA-N 0.000 claims 1
OWJJLIMTLAUXSY-NKVSQWTQSA-N (2z)-2-[(4-chloro-3-nitrophenyl)methylidene]-6-[(2,6-dichlorophenyl)methylsulfonyl]-4h-1,4-benzothiazin-3-one Chemical compound C1=C(Cl)C([N+](=O)[O-])=CC(\C=C/2C(NC3=CC(=CC=C3S\2)S(=O)(=O)CC=2C(=CC=CC=2Cl)Cl)=O)=C1 OWJJLIMTLAUXSY-NKVSQWTQSA-N 0.000 claims 1
CSCTZSRXMZNQRE-NKVSQWTQSA-N (2z)-2-[(4-chloro-3-nitrophenyl)methylidene]-6-[(2,6-difluorophenyl)methylsulfonyl]-4h-1,4-benzothiazin-3-one Chemical compound C1=C(Cl)C([N+](=O)[O-])=CC(\C=C/2C(NC3=CC(=CC=C3S\2)S(=O)(=O)CC=2C(=CC=CC=2F)F)=O)=C1 CSCTZSRXMZNQRE-NKVSQWTQSA-N 0.000 claims 1
LUWIZFPLOQVUNG-KSEXSDGBSA-N (2z)-2-[(4-chloro-3-nitrophenyl)methylidene]-6-[(2,6-dimethoxyphenyl)methylsulfonyl]-4h-1,4-benzothiazin-3-one Chemical compound COC1=CC=CC(OC)=C1CS(=O)(=O)C1=CC=C(S\C(=C/C=2C=C(C(Cl)=CC=2)[N+]([O-])=O)C(=O)N2)C2=C1 LUWIZFPLOQVUNG-KSEXSDGBSA-N 0.000 claims 1
BWDIAKKLICNVDB-KSEXSDGBSA-N (2z)-2-[(4-chloro-3-nitrophenyl)methylidene]-6-[(2,6-dimethylphenyl)methylsulfonyl]-4h-1,4-benzothiazin-3-one Chemical compound CC1=CC=CC(C)=C1CS(=O)(=O)C1=CC=C(S\C(=C/C=2C=C(C(Cl)=CC=2)[N+]([O-])=O)C(=O)N2)C2=C1 BWDIAKKLICNVDB-KSEXSDGBSA-N 0.000 claims 1
ZJPASQYSCJHTPA-FBHDLOMBSA-N (2z)-2-[(4-chlorophenyl)methylidene]-6-[(2,6-dibromophenyl)methylsulfonyl]-4h-1,4-benzothiazin-3-one Chemical compound C1=CC(Cl)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3Br)Br)=CC=C2S\1 ZJPASQYSCJHTPA-FBHDLOMBSA-N 0.000 claims 1
OXEMNSUDEJOOQD-FBHDLOMBSA-N (2z)-2-[(4-chlorophenyl)methylidene]-6-[(2,6-dichlorophenyl)methylsulfonyl]-4h-1,4-benzothiazin-3-one Chemical compound C1=CC(Cl)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3Cl)Cl)=CC=C2S\1 OXEMNSUDEJOOQD-FBHDLOMBSA-N 0.000 claims 1
QHVMXLIGMPXPGR-FBHDLOMBSA-N (2z)-2-[(4-chlorophenyl)methylidene]-6-[(2,6-difluorophenyl)methylsulfonyl]-4h-1,4-benzothiazin-3-one Chemical compound FC1=CC=CC(F)=C1CS(=O)(=O)C1=CC=C(S\C(=C/C=2C=CC(Cl)=CC=2)C(=O)N2)C2=C1 QHVMXLIGMPXPGR-FBHDLOMBSA-N 0.000 claims 1
FXWIXIQTCVYBID-FMCGGJTJSA-N (2z)-2-[(4-chlorophenyl)methylidene]-6-[(2,6-dimethoxyphenyl)methylsulfonyl]-4h-1,4-benzothiazin-3-one Chemical compound COC1=CC=CC(OC)=C1CS(=O)(=O)C1=CC=C(S\C(=C/C=2C=CC(Cl)=CC=2)C(=O)N2)C2=C1 FXWIXIQTCVYBID-FMCGGJTJSA-N 0.000 claims 1
JGNUPZVBDOABLK-FMCGGJTJSA-N (2z)-2-[(4-chlorophenyl)methylidene]-6-[(2,6-dimethylphenyl)methylsulfonyl]-4h-1,4-benzothiazin-3-one Chemical compound CC1=CC=CC(C)=C1CS(=O)(=O)C1=CC=C(S\C(=C/C=2C=CC(Cl)=CC=2)C(=O)N2)C2=C1 JGNUPZVBDOABLK-FMCGGJTJSA-N 0.000 claims 1
OBXRZQKXGZATAI-NHDPSOOVSA-N (2z)-2-benzylidene-6-[(2,6-dibromophenyl)methylsulfonyl]-4h-1,4-benzothiazin-3-one Chemical compound BrC1=CC=CC(Br)=C1CS(=O)(=O)C1=CC=C(S\C(=C/C=2C=CC=CC=2)C(=O)N2)C2=C1 OBXRZQKXGZATAI-NHDPSOOVSA-N 0.000 claims 1
INLCAGDYZDWDFN-NHDPSOOVSA-N (2z)-2-benzylidene-6-[(2,6-dichlorophenyl)methylsulfonyl]-4h-1,4-benzothiazin-3-one Chemical compound ClC1=CC=CC(Cl)=C1CS(=O)(=O)C1=CC=C(S\C(=C/C=2C=CC=CC=2)C(=O)N2)C2=C1 INLCAGDYZDWDFN-NHDPSOOVSA-N 0.000 claims 1
RQUMEVLBANUEKF-NHDPSOOVSA-N (2z)-2-benzylidene-6-[(2,6-difluorophenyl)methylsulfonyl]-4h-1,4-benzothiazin-3-one Chemical compound FC1=CC=CC(F)=C1CS(=O)(=O)C1=CC=C(S\C(=C/C=2C=CC=CC=2)C(=O)N2)C2=C1 RQUMEVLBANUEKF-NHDPSOOVSA-N 0.000 claims 1
OKNYPNMYXHHVQU-QRVIBDJDSA-N (2z)-2-benzylidene-6-[(2,6-dimethoxyphenyl)methylsulfonyl]-4h-1,4-benzothiazin-3-one Chemical compound COC1=CC=CC(OC)=C1CS(=O)(=O)C1=CC=C(S\C(=C/C=2C=CC=CC=2)C(=O)N2)C2=C1 OKNYPNMYXHHVQU-QRVIBDJDSA-N 0.000 claims 1
TWCZQMWRTPPIBX-QRVIBDJDSA-N (2z)-2-benzylidene-6-[(2,6-dimethylphenyl)methylsulfonyl]-4h-1,4-benzothiazin-3-one Chemical compound CC1=CC=CC(C)=C1CS(=O)(=O)C1=CC=C(S\C(=C/C=2C=CC=CC=2)C(=O)N2)C2=C1 TWCZQMWRTPPIBX-QRVIBDJDSA-N 0.000 claims 1
HVROFBZTYIXYFQ-MSXFZWOLSA-N (2z)-6-[(2,6-dibromophenyl)methylsulfonyl]-2-[(2,4,6-trimethoxyphenyl)methylidene]-4h-1,4-benzothiazin-3-one Chemical compound COC1=CC(OC)=CC(OC)=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3Br)Br)=CC=C2S\1 HVROFBZTYIXYFQ-MSXFZWOLSA-N 0.000 claims 1
PDEMRQRFFHCNQN-WNFQYIGGSA-N (2z)-6-[(2,6-dibromophenyl)methylsulfonyl]-2-[(2,4-difluorophenyl)methylidene]-4h-1,4-benzothiazin-3-one Chemical compound FC1=CC(F)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3Br)Br)=CC=C2S\1 PDEMRQRFFHCNQN-WNFQYIGGSA-N 0.000 claims 1
DGLCCPVSEASPAS-MUXKCCDJSA-N (2z)-6-[(2,6-dibromophenyl)methylsulfonyl]-2-[(3-nitro-4-phenylmethoxyphenyl)methylidene]-4h-1,4-benzothiazin-3-one Chemical compound C=1C=C(OCC=2C=CC=CC=2)C([N+](=O)[O-])=CC=1\C=C(C(NC1=C2)=O)/SC1=CC=C2S(=O)(=O)CC1=C(Br)C=CC=C1Br DGLCCPVSEASPAS-MUXKCCDJSA-N 0.000 claims 1
GNHLVDJEKYAEBA-FBHDLOMBSA-N (2z)-6-[(2,6-dibromophenyl)methylsulfonyl]-2-[(4-fluorophenyl)methylidene]-4h-1,4-benzothiazin-3-one Chemical compound C1=CC(F)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3Br)Br)=CC=C2S\1 GNHLVDJEKYAEBA-FBHDLOMBSA-N 0.000 claims 1
HYGGULMPJXCGSU-KSEXSDGBSA-N (2z)-6-[(2,6-dibromophenyl)methylsulfonyl]-2-[(4-hydroxy-2,6-dimethoxyphenyl)methylidene]-4h-1,4-benzothiazin-3-one Chemical compound COC1=CC(O)=CC(OC)=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3Br)Br)=CC=C2S\1 HYGGULMPJXCGSU-KSEXSDGBSA-N 0.000 claims 1
VGKKMZMOFYUWTH-NKVSQWTQSA-N (2z)-6-[(2,6-dibromophenyl)methylsulfonyl]-2-[(4-hydroxy-3-nitrophenyl)methylidene]-4h-1,4-benzothiazin-3-one Chemical compound C1=C([N+]([O-])=O)C(O)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3Br)Br)=CC=C2S\1 VGKKMZMOFYUWTH-NKVSQWTQSA-N 0.000 claims 1
HGDHQAAOEMXYKB-YVNNLAQVSA-N (2z)-6-[(2,6-dibromophenyl)methylsulfonyl]-2-[(4-methoxy-3-nitrophenyl)methylidene]-4h-1,4-benzothiazin-3-one Chemical compound C1=C([N+]([O-])=O)C(OC)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3Br)Br)=CC=C2S\1 HGDHQAAOEMXYKB-YVNNLAQVSA-N 0.000 claims 1
TWNWAZORDNJJMK-JJFYIABZSA-N (2z)-6-[(2,6-dibromophenyl)methylsulfonyl]-2-[(4-methoxyphenyl)methylidene]-4h-1,4-benzothiazin-3-one Chemical compound C1=CC(OC)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3Br)Br)=CC=C2S\1 TWNWAZORDNJJMK-JJFYIABZSA-N 0.000 claims 1
BXSXCOYWLUIOAR-JJFYIABZSA-N (2z)-6-[(2,6-dibromophenyl)methylsulfonyl]-2-[(4-methylphenyl)methylidene]-4h-1,4-benzothiazin-3-one Chemical compound C1=CC(C)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3Br)Br)=CC=C2S\1 BXSXCOYWLUIOAR-JJFYIABZSA-N 0.000 claims 1
SJZGYDQPSGLFRK-FBHDLOMBSA-N (2z)-6-[(2,6-dibromophenyl)methylsulfonyl]-2-[(4-nitrophenyl)methylidene]-4h-1,4-benzothiazin-3-one Chemical compound C1=CC([N+](=O)[O-])=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3Br)Br)=CC=C2S\1 SJZGYDQPSGLFRK-FBHDLOMBSA-N 0.000 claims 1
ORIWDKHRILISCH-FBHDLOMBSA-N (2z)-6-[(2,6-dibromophenyl)methylsulfonyl]-2-[[4-(2h-tetrazol-5-yl)phenyl]methylidene]-4h-1,4-benzothiazin-3-one Chemical compound BrC1=CC=CC(Br)=C1CS(=O)(=O)C1=CC=C(S\C(=C/C=2C=CC(=CC=2)C2=NNN=N2)C(=O)N2)C2=C1 ORIWDKHRILISCH-FBHDLOMBSA-N 0.000 claims 1
CFYFPBHLMNVODE-YSMPRRRNSA-N (2z)-6-[(2,6-dibromophenyl)methylsulfonyl]-2-[[4-(4-methylpiperazin-1-yl)phenyl]methylidene]-4h-1,4-benzothiazin-3-one Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3Br)Br)=CC=C2S\1 CFYFPBHLMNVODE-YSMPRRRNSA-N 0.000 claims 1
ONALIGAXULKPNX-RMORIDSASA-N (2z)-6-[(2,6-dichlorophenyl)methylsulfonyl]-2-(1h-indol-3-ylmethylidene)-4h-1,4-benzothiazin-3-one Chemical compound ClC1=CC=CC(Cl)=C1CS(=O)(=O)C1=CC=C(S\C(=C/C=2C3=CC=CC=C3NC=2)C(=O)N2)C2=C1 ONALIGAXULKPNX-RMORIDSASA-N 0.000 claims 1
QKHSEQYCHUPHPI-UWVJOHFNSA-N (2z)-6-[(2,6-dichlorophenyl)methylsulfonyl]-2-(1h-pyrrol-3-ylmethylidene)-4h-1,4-benzothiazin-3-one Chemical compound ClC1=CC=CC(Cl)=C1CS(=O)(=O)C1=CC=C(S\C(=C/C2=CNC=C2)C(=O)N2)C2=C1 QKHSEQYCHUPHPI-UWVJOHFNSA-N 0.000 claims 1
WRCSUQCHJHTZRJ-OCKHKDLRSA-N (2z)-6-[(2,6-dichlorophenyl)methylsulfonyl]-2-(thiophen-2-ylmethylidene)-4h-1,4-benzothiazin-3-one Chemical compound ClC1=CC=CC(Cl)=C1CS(=O)(=O)C1=CC=C(S\C(=C/C=2SC=CC=2)C(=O)N2)C2=C1 WRCSUQCHJHTZRJ-OCKHKDLRSA-N 0.000 claims 1
VEWQFVNYWCVKJL-MSXFZWOLSA-N (2z)-6-[(2,6-dichlorophenyl)methylsulfonyl]-2-[(2,4,6-trimethoxyphenyl)methylidene]-4h-1,4-benzothiazin-3-one Chemical compound COC1=CC(OC)=CC(OC)=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3Cl)Cl)=CC=C2S\1 VEWQFVNYWCVKJL-MSXFZWOLSA-N 0.000 claims 1
AZPXYTJKKUXYCY-WNFQYIGGSA-N (2z)-6-[(2,6-dichlorophenyl)methylsulfonyl]-2-[(2,4-difluorophenyl)methylidene]-4h-1,4-benzothiazin-3-one Chemical compound FC1=CC(F)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3Cl)Cl)=CC=C2S\1 AZPXYTJKKUXYCY-WNFQYIGGSA-N 0.000 claims 1
KMERYAKQOVSQNN-OCKHKDLRSA-N (2z)-6-[(2,6-dichlorophenyl)methylsulfonyl]-2-[(2-methylsulfanylpyrimidin-4-yl)methylidene]-4h-1,4-benzothiazin-3-one Chemical compound CSC1=NC=CC(\C=C/2C(NC3=CC(=CC=C3S\2)S(=O)(=O)CC=2C(=CC=CC=2Cl)Cl)=O)=N1 KMERYAKQOVSQNN-OCKHKDLRSA-N 0.000 claims 1
CCXBPGYSYVDWTO-UUYOSTAYSA-N (2z)-6-[(2,6-dichlorophenyl)methylsulfonyl]-2-[(2-morpholin-4-ylpyrimidin-4-yl)methylidene]-4h-1,4-benzothiazin-3-one Chemical compound ClC1=CC=CC(Cl)=C1CS(=O)(=O)C1=CC=C(S\C(=C/C=2N=C(N=CC=2)N2CCOCC2)C(=O)N2)C2=C1 CCXBPGYSYVDWTO-UUYOSTAYSA-N 0.000 claims 1
DDWDHRRZRFLSIV-MUXKCCDJSA-N (2z)-6-[(2,6-dichlorophenyl)methylsulfonyl]-2-[(3-nitro-4-phenylmethoxyphenyl)methylidene]-4h-1,4-benzothiazin-3-one Chemical compound C=1C=C(OCC=2C=CC=CC=2)C([N+](=O)[O-])=CC=1\C=C(C(NC1=C2)=O)/SC1=CC=C2S(=O)(=O)CC1=C(Cl)C=CC=C1Cl DDWDHRRZRFLSIV-MUXKCCDJSA-N 0.000 claims 1
KQUBNSASCGENME-FBHDLOMBSA-N (2z)-6-[(2,6-dichlorophenyl)methylsulfonyl]-2-[(4-fluorophenyl)methylidene]-4h-1,4-benzothiazin-3-one Chemical compound C1=CC(F)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3Cl)Cl)=CC=C2S\1 KQUBNSASCGENME-FBHDLOMBSA-N 0.000 claims 1
KZENOQQFUZESTN-KSEXSDGBSA-N (2z)-6-[(2,6-dichlorophenyl)methylsulfonyl]-2-[(4-hydroxy-2,6-dimethoxyphenyl)methylidene]-4h-1,4-benzothiazin-3-one Chemical compound COC1=CC(O)=CC(OC)=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3Cl)Cl)=CC=C2S\1 KZENOQQFUZESTN-KSEXSDGBSA-N 0.000 claims 1
ZQLNYXYDGXSMLX-YVNNLAQVSA-N (2z)-6-[(2,6-dichlorophenyl)methylsulfonyl]-2-[(4-methoxy-3-nitrophenyl)methylidene]-4h-1,4-benzothiazin-3-one Chemical compound C1=C([N+]([O-])=O)C(OC)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3Cl)Cl)=CC=C2S\1 ZQLNYXYDGXSMLX-YVNNLAQVSA-N 0.000 claims 1
ROWQLZKOUXMXIK-JJFYIABZSA-N (2z)-6-[(2,6-dichlorophenyl)methylsulfonyl]-2-[(4-methoxyphenyl)methylidene]-4h-1,4-benzothiazin-3-one Chemical compound C1=CC(OC)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3Cl)Cl)=CC=C2S\1 ROWQLZKOUXMXIK-JJFYIABZSA-N 0.000 claims 1
VGULYMVHMPDOIN-JJFYIABZSA-N (2z)-6-[(2,6-dichlorophenyl)methylsulfonyl]-2-[(4-methylphenyl)methylidene]-4h-1,4-benzothiazin-3-one Chemical compound C1=CC(C)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3Cl)Cl)=CC=C2S\1 VGULYMVHMPDOIN-JJFYIABZSA-N 0.000 claims 1
GJEHDZRNMVRKGG-FBHDLOMBSA-N (2z)-6-[(2,6-dichlorophenyl)methylsulfonyl]-2-[(4-nitrophenyl)methylidene]-4h-1,4-benzothiazin-3-one Chemical compound C1=CC([N+](=O)[O-])=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3Cl)Cl)=CC=C2S\1 GJEHDZRNMVRKGG-FBHDLOMBSA-N 0.000 claims 1
DXUOXRZSEDQPDT-FBHDLOMBSA-N (2z)-6-[(2,6-dichlorophenyl)methylsulfonyl]-2-[[4-(2h-tetrazol-5-yl)phenyl]methylidene]-4h-1,4-benzothiazin-3-one Chemical compound ClC1=CC=CC(Cl)=C1CS(=O)(=O)C1=CC=C(S\C(=C/C=2C=CC(=CC=2)C2=NNN=N2)C(=O)N2)C2=C1 DXUOXRZSEDQPDT-FBHDLOMBSA-N 0.000 claims 1
KNCUBEXHYKLKMS-YSMPRRRNSA-N (2z)-6-[(2,6-dichlorophenyl)methylsulfonyl]-2-[[4-(4-methylpiperazin-1-yl)phenyl]methylidene]-4h-1,4-benzothiazin-3-one Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3Cl)Cl)=CC=C2S\1 KNCUBEXHYKLKMS-YSMPRRRNSA-N 0.000 claims 1
BVYQXBMFXNPLQD-NKVSQWTQSA-N (2z)-6-[(2,6-difluorophenyl)methylsulfonyl]-2-[(2,4,6-trifluorophenyl)methylidene]-4h-1,4-benzothiazin-3-one Chemical compound FC1=CC(F)=CC(F)=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3F)F)=CC=C2S\1 BVYQXBMFXNPLQD-NKVSQWTQSA-N 0.000 claims 1
JMUMHAICFSUHBL-MSXFZWOLSA-N (2z)-6-[(2,6-difluorophenyl)methylsulfonyl]-2-[(2,4,6-trimethoxyphenyl)methylidene]-4h-1,4-benzothiazin-3-one Chemical compound COC1=CC(OC)=CC(OC)=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3F)F)=CC=C2S\1 JMUMHAICFSUHBL-MSXFZWOLSA-N 0.000 claims 1
KENYSUJZAWZOCV-MUXKCCDJSA-N (2z)-6-[(2,6-difluorophenyl)methylsulfonyl]-2-[(3-nitro-4-phenylmethoxyphenyl)methylidene]-4h-1,4-benzothiazin-3-one Chemical compound C=1C=C(OCC=2C=CC=CC=2)C([N+](=O)[O-])=CC=1\C=C(C(NC1=C2)=O)/SC1=CC=C2S(=O)(=O)CC1=C(F)C=CC=C1F KENYSUJZAWZOCV-MUXKCCDJSA-N 0.000 claims 1
UEUHDURWVIDESN-FBHDLOMBSA-N (2z)-6-[(2,6-difluorophenyl)methylsulfonyl]-2-[(4-fluorophenyl)methylidene]-4h-1,4-benzothiazin-3-one Chemical compound C1=CC(F)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3F)F)=CC=C2S\1 UEUHDURWVIDESN-FBHDLOMBSA-N 0.000 claims 1
MCHUWOUMDZWDFG-KSEXSDGBSA-N (2z)-6-[(2,6-difluorophenyl)methylsulfonyl]-2-[(4-hydroxy-2,6-dimethoxyphenyl)methylidene]-4h-1,4-benzothiazin-3-one Chemical compound COC1=CC(O)=CC(OC)=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3F)F)=CC=C2S\1 MCHUWOUMDZWDFG-KSEXSDGBSA-N 0.000 claims 1
DCEPBZIYWZFEPX-NKVSQWTQSA-N (2z)-6-[(2,6-difluorophenyl)methylsulfonyl]-2-[(4-hydroxy-3-nitrophenyl)methylidene]-4h-1,4-benzothiazin-3-one Chemical compound C1=C([N+]([O-])=O)C(O)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3F)F)=CC=C2S\1 DCEPBZIYWZFEPX-NKVSQWTQSA-N 0.000 claims 1
ADOZXOLHCCZLNZ-YVNNLAQVSA-N (2z)-6-[(2,6-difluorophenyl)methylsulfonyl]-2-[(4-methoxy-3-nitrophenyl)methylidene]-4h-1,4-benzothiazin-3-one Chemical compound C1=C([N+]([O-])=O)C(OC)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3F)F)=CC=C2S\1 ADOZXOLHCCZLNZ-YVNNLAQVSA-N 0.000 claims 1
FGFDZIJIEKXDGF-JJFYIABZSA-N (2z)-6-[(2,6-difluorophenyl)methylsulfonyl]-2-[(4-methoxyphenyl)methylidene]-4h-1,4-benzothiazin-3-one Chemical compound C1=CC(OC)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3F)F)=CC=C2S\1 FGFDZIJIEKXDGF-JJFYIABZSA-N 0.000 claims 1
LIJDNZYOIXRLSH-JJFYIABZSA-N (2z)-6-[(2,6-difluorophenyl)methylsulfonyl]-2-[(4-methylphenyl)methylidene]-4h-1,4-benzothiazin-3-one Chemical compound C1=CC(C)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3F)F)=CC=C2S\1 LIJDNZYOIXRLSH-JJFYIABZSA-N 0.000 claims 1
BMTQUXFESDAUSW-FBHDLOMBSA-N (2z)-6-[(2,6-difluorophenyl)methylsulfonyl]-2-[(4-nitrophenyl)methylidene]-4h-1,4-benzothiazin-3-one Chemical compound C1=CC([N+](=O)[O-])=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3F)F)=CC=C2S\1 BMTQUXFESDAUSW-FBHDLOMBSA-N 0.000 claims 1
SNDRIVIWLYZITM-FBHDLOMBSA-N (2z)-6-[(2,6-difluorophenyl)methylsulfonyl]-2-[[4-(2h-tetrazol-5-yl)phenyl]methylidene]-4h-1,4-benzothiazin-3-one Chemical compound FC1=CC=CC(F)=C1CS(=O)(=O)C1=CC=C(S\C(=C/C=2C=CC(=CC=2)C2=NNN=N2)C(=O)N2)C2=C1 SNDRIVIWLYZITM-FBHDLOMBSA-N 0.000 claims 1
DIUXFABQHYPHNV-YSMPRRRNSA-N (2z)-6-[(2,6-difluorophenyl)methylsulfonyl]-2-[[4-(4-methylpiperazin-1-yl)phenyl]methylidene]-4h-1,4-benzothiazin-3-one Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3F)F)=CC=C2S\1 DIUXFABQHYPHNV-YSMPRRRNSA-N 0.000 claims 1
NNJVDCPLKKJTKY-FMCGGJTJSA-N (2z)-6-[(2,6-dimethoxyphenyl)methylsulfonyl]-2-[(4-fluorophenyl)methylidene]-4h-1,4-benzothiazin-3-one Chemical compound COC1=CC=CC(OC)=C1CS(=O)(=O)C1=CC=C(S\C(=C/C=2C=CC(F)=CC=2)C(=O)N2)C2=C1 NNJVDCPLKKJTKY-FMCGGJTJSA-N 0.000 claims 1
ZTSZZHJUEWNZDE-MXAYSNPKSA-N (2z)-6-[(2,6-dimethoxyphenyl)methylsulfonyl]-2-[(4-hydroxy-2,6-dimethoxyphenyl)methylidene]-4h-1,4-benzothiazin-3-one Chemical compound COC1=CC=CC(OC)=C1CS(=O)(=O)C1=CC=C(S\C(=C/C=2C(=CC(O)=CC=2OC)OC)C(=O)N2)C2=C1 ZTSZZHJUEWNZDE-MXAYSNPKSA-N 0.000 claims 1
UYFQDVBWPFDDIO-MSXFZWOLSA-N (2z)-6-[(2,6-dimethoxyphenyl)methylsulfonyl]-2-[(4-methoxy-3-nitrophenyl)methylidene]-4h-1,4-benzothiazin-3-one Chemical compound COC1=CC=CC(OC)=C1CS(=O)(=O)C1=CC=C(S\C(=C/C=2C=C(C(OC)=CC=2)[N+]([O-])=O)C(=O)N2)C2=C1 UYFQDVBWPFDDIO-MSXFZWOLSA-N 0.000 claims 1
MHZOQRAVLBQFMC-CFRMEGHHSA-N (2z)-6-[(2,6-dimethoxyphenyl)methylsulfonyl]-2-[(4-methoxyphenyl)methylidene]-4h-1,4-benzothiazin-3-one Chemical compound C1=CC(OC)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3OC)OC)=CC=C2S\1 MHZOQRAVLBQFMC-CFRMEGHHSA-N 0.000 claims 1
QWFLWLRYBCQEGN-CFRMEGHHSA-N (2z)-6-[(2,6-dimethoxyphenyl)methylsulfonyl]-2-[(4-methylphenyl)methylidene]-4h-1,4-benzothiazin-3-one Chemical compound COC1=CC=CC(OC)=C1CS(=O)(=O)C1=CC=C(S\C(=C/C=2C=CC(C)=CC=2)C(=O)N2)C2=C1 QWFLWLRYBCQEGN-CFRMEGHHSA-N 0.000 claims 1
QLVFNNUIEARQOG-FMCGGJTJSA-N (2z)-6-[(2,6-dimethoxyphenyl)methylsulfonyl]-2-[(4-nitrophenyl)methylidene]-4h-1,4-benzothiazin-3-one Chemical compound COC1=CC=CC(OC)=C1CS(=O)(=O)C1=CC=C(S\C(=C/C=2C=CC(=CC=2)[N+]([O-])=O)C(=O)N2)C2=C1 QLVFNNUIEARQOG-FMCGGJTJSA-N 0.000 claims 1
LDHCWRYFOYSCQS-QRQIAZFYSA-N (2z)-6-[(2,6-dimethoxyphenyl)methylsulfonyl]-2-[[4-(4-methylpiperazin-1-yl)phenyl]methylidene]-4h-1,4-benzothiazin-3-one Chemical compound COC1=CC=CC(OC)=C1CS(=O)(=O)C1=CC=C(S\C(=C/C=2C=CC(=CC=2)N2CCN(C)CC2)C(=O)N2)C2=C1 LDHCWRYFOYSCQS-QRQIAZFYSA-N 0.000 claims 1
YGYYYBQDFGPEDC-WGARJPEWSA-N (2z)-6-[(2,6-dimethylphenyl)methylsulfonyl]-2-[(2,4,6-trimethoxyphenyl)methylidene]-4h-1,4-benzothiazin-3-one Chemical compound COC1=CC(OC)=CC(OC)=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3C)C)=CC=C2S\1 YGYYYBQDFGPEDC-WGARJPEWSA-N 0.000 claims 1
CYIZGNAYDJALLZ-UHBFCERESA-N (2z)-6-[(2,6-dimethylphenyl)methylsulfonyl]-2-[(3-nitro-4-phenylmethoxyphenyl)methylidene]-4h-1,4-benzothiazin-3-one Chemical compound CC1=CC=CC(C)=C1CS(=O)(=O)C1=CC=C(S\C(=C/C=2C=C(C(OCC=3C=CC=CC=3)=CC=2)[N+]([O-])=O)C(=O)N2)C2=C1 CYIZGNAYDJALLZ-UHBFCERESA-N 0.000 claims 1
KHFUWXZDLPJXJF-FMCGGJTJSA-N (2z)-6-[(2,6-dimethylphenyl)methylsulfonyl]-2-[(4-fluorophenyl)methylidene]-4h-1,4-benzothiazin-3-one Chemical compound CC1=CC=CC(C)=C1CS(=O)(=O)C1=CC=C(S\C(=C/C=2C=CC(F)=CC=2)C(=O)N2)C2=C1 KHFUWXZDLPJXJF-FMCGGJTJSA-N 0.000 claims 1
QORJCTUAVYOMHS-MXAYSNPKSA-N (2z)-6-[(2,6-dimethylphenyl)methylsulfonyl]-2-[(4-hydroxy-2,6-dimethoxyphenyl)methylidene]-4h-1,4-benzothiazin-3-one Chemical compound COC1=CC(O)=CC(OC)=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3C)C)=CC=C2S\1 QORJCTUAVYOMHS-MXAYSNPKSA-N 0.000 claims 1
FGXPAGUDEISZMS-KSEXSDGBSA-N (2z)-6-[(2,6-dimethylphenyl)methylsulfonyl]-2-[(4-hydroxy-3-nitrophenyl)methylidene]-4h-1,4-benzothiazin-3-one Chemical compound CC1=CC=CC(C)=C1CS(=O)(=O)C1=CC=C(S\C(=C/C=2C=C(C(O)=CC=2)[N+]([O-])=O)C(=O)N2)C2=C1 FGXPAGUDEISZMS-KSEXSDGBSA-N 0.000 claims 1
CGQXNCWMYRQXHK-MSXFZWOLSA-N (2z)-6-[(2,6-dimethylphenyl)methylsulfonyl]-2-[(4-methoxy-3-nitrophenyl)methylidene]-4h-1,4-benzothiazin-3-one Chemical compound C1=C([N+]([O-])=O)C(OC)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3C)C)=CC=C2S\1 CGQXNCWMYRQXHK-MSXFZWOLSA-N 0.000 claims 1
LRHZUVONCRTNES-CFRMEGHHSA-N (2z)-6-[(2,6-dimethylphenyl)methylsulfonyl]-2-[(4-methoxyphenyl)methylidene]-4h-1,4-benzothiazin-3-one Chemical compound C1=CC(OC)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3C)C)=CC=C2S\1 LRHZUVONCRTNES-CFRMEGHHSA-N 0.000 claims 1
UJCBPBDTPLUCBU-CFRMEGHHSA-N (2z)-6-[(2,6-dimethylphenyl)methylsulfonyl]-2-[(4-methylphenyl)methylidene]-4h-1,4-benzothiazin-3-one Chemical compound C1=CC(C)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3C)C)=CC=C2S\1 UJCBPBDTPLUCBU-CFRMEGHHSA-N 0.000 claims 1
BKUBUBQQSRLZPD-FMCGGJTJSA-N (2z)-6-[(2,6-dimethylphenyl)methylsulfonyl]-2-[(4-nitrophenyl)methylidene]-4h-1,4-benzothiazin-3-one Chemical compound CC1=CC=CC(C)=C1CS(=O)(=O)C1=CC=C(S\C(=C/C=2C=CC(=CC=2)[N+]([O-])=O)C(=O)N2)C2=C1 BKUBUBQQSRLZPD-FMCGGJTJSA-N 0.000 claims 1
125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims 1
FKCYWJFEUYIFGG-YVNNLAQVSA-N 2-[4-[(z)-[6-[(2,6-dibromophenyl)methylsulfonyl]-3-oxo-4h-1,4-benzothiazin-2-ylidene]methyl]anilino]acetic acid Chemical compound C1=CC(NCC(=O)O)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3Br)Br)=CC=C2S\1 FKCYWJFEUYIFGG-YVNNLAQVSA-N 0.000 claims 1
LDARZSCMGBDSBA-YVNNLAQVSA-N 2-[4-[(z)-[6-[(2,6-dichlorophenyl)methylsulfonyl]-3-oxo-4h-1,4-benzothiazin-2-ylidene]methyl]anilino]acetic acid Chemical compound C1=CC(NCC(=O)O)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3Cl)Cl)=CC=C2S\1 LDARZSCMGBDSBA-YVNNLAQVSA-N 0.000 claims 1
STURAVBBHYALGE-YVNNLAQVSA-N 2-[4-[(z)-[6-[(2,6-difluorophenyl)methylsulfonyl]-3-oxo-4h-1,4-benzothiazin-2-ylidene]methyl]anilino]acetic acid Chemical compound C1=CC(NCC(=O)O)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3F)F)=CC=C2S\1 STURAVBBHYALGE-YVNNLAQVSA-N 0.000 claims 1
IKPYZRHEWVAFPO-MSXFZWOLSA-N 2-[4-[(z)-[6-[(2,6-dimethylphenyl)methylsulfonyl]-3-oxo-4h-1,4-benzothiazin-2-ylidene]methyl]anilino]acetic acid Chemical compound CC1=CC=CC(C)=C1CS(=O)(=O)C1=CC=C(S\C(=C/C=2C=CC(NCC(O)=O)=CC=2)C(=O)N2)C2=C1 IKPYZRHEWVAFPO-MSXFZWOLSA-N 0.000 claims 1
229910004878 Na2S2O4 Inorganic materials 0.000 claims 1
UZWBUWSOHMQWCR-OCKHKDLRSA-N [4-[(z)-(4-acetyl-7-methoxy-3-oxo-1,4-benzothiazin-2-ylidene)methyl]-2-nitrophenyl] acetate Chemical compound S1C2=CC(OC)=CC=C2N(C(C)=O)C(=O)\C1=C\C1=CC=C(OC(C)=O)C([N+]([O-])=O)=C1 UZWBUWSOHMQWCR-OCKHKDLRSA-N 0.000 claims 1
JDIMUUXYSILPPU-APSNUPSMSA-N [4-[(z)-(6-fluoro-3-oxo-4h-1,4-benzothiazin-2-ylidene)methyl]-2-nitrophenyl] acetate Chemical compound C1=C([N+]([O-])=O)C(OC(=O)C)=CC=C1\C=C/1C(=O)NC2=CC(F)=CC=C2S\1 JDIMUUXYSILPPU-APSNUPSMSA-N 0.000 claims 1
IVTKWEIJERLKGZ-APSNUPSMSA-N [4-[(z)-(7-fluoro-3-oxo-4h-1,4-benzothiazin-2-ylidene)methyl]-2-nitrophenyl] acetate Chemical compound C1=C([N+]([O-])=O)C(OC(=O)C)=CC=C1\C=C/1C(=O)NC2=CC=C(F)C=C2S\1 IVTKWEIJERLKGZ-APSNUPSMSA-N 0.000 claims 1
AXHRZNFXWPCMFR-MFOYZWKCSA-N [4-[(z)-(7-methyl-3-oxo-4h-1,4-benzothiazin-2-ylidene)methyl]-2-nitrophenyl] acetate Chemical compound C1=C([N+]([O-])=O)C(OC(=O)C)=CC=C1\C=C/1C(=O)NC2=CC=C(C)C=C2S\1 AXHRZNFXWPCMFR-MFOYZWKCSA-N 0.000 claims 1
GADUAKFJGHBTGK-MUXKCCDJSA-N [4-[(z)-[6-[(2,6-dibromophenyl)methylsulfonyl]-3-oxo-4h-1,4-benzothiazin-2-ylidene]methyl]-2-nitrophenyl] 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OC(C(=C1)[N+]([O-])=O)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3Br)Br)=CC=C2S\1 GADUAKFJGHBTGK-MUXKCCDJSA-N 0.000 claims 1
OIBWKWNKBWDPMA-RMORIDSASA-N [4-[(z)-[6-[(2,6-dibromophenyl)methylsulfonyl]-3-oxo-4h-1,4-benzothiazin-2-ylidene]methyl]-2-nitrophenyl] acetate Chemical compound C1=C([N+]([O-])=O)C(OC(=O)C)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3Br)Br)=CC=C2S\1 OIBWKWNKBWDPMA-RMORIDSASA-N 0.000 claims 1
HRZBWYLWPLEUAE-KSEXSDGBSA-N [4-[(z)-[6-[(2,6-dibromophenyl)methylsulfonyl]-3-oxo-4h-1,4-benzothiazin-2-ylidene]methyl]phenyl] acetate Chemical compound C1=CC(OC(=O)C)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3Br)Br)=CC=C2S\1 HRZBWYLWPLEUAE-KSEXSDGBSA-N 0.000 claims 1
ZYWFZBOQXFLORF-MUXKCCDJSA-N [4-[(z)-[6-[(2,6-dichlorophenyl)methylsulfonyl]-3-oxo-4h-1,4-benzothiazin-2-ylidene]methyl]-2-nitrophenyl] 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OC(C(=C1)[N+]([O-])=O)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3Cl)Cl)=CC=C2S\1 ZYWFZBOQXFLORF-MUXKCCDJSA-N 0.000 claims 1
TWMQABSIQGOAPU-RMORIDSASA-N [4-[(z)-[6-[(2,6-dichlorophenyl)methylsulfonyl]-3-oxo-4h-1,4-benzothiazin-2-ylidene]methyl]-2-nitrophenyl] acetate Chemical compound C1=C([N+]([O-])=O)C(OC(=O)C)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3Cl)Cl)=CC=C2S\1 TWMQABSIQGOAPU-RMORIDSASA-N 0.000 claims 1
YVGKZASUGDBLLV-KSEXSDGBSA-N [4-[(z)-[6-[(2,6-dichlorophenyl)methylsulfonyl]-3-oxo-4h-1,4-benzothiazin-2-ylidene]methyl]phenyl] acetate Chemical compound C1=CC(OC(=O)C)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3Cl)Cl)=CC=C2S\1 YVGKZASUGDBLLV-KSEXSDGBSA-N 0.000 claims 1
RWQPYMGVFOZQCK-MUXKCCDJSA-N [4-[(z)-[6-[(2,6-difluorophenyl)methylsulfonyl]-3-oxo-4h-1,4-benzothiazin-2-ylidene]methyl]-2-nitrophenyl] 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OC(C(=C1)[N+]([O-])=O)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3F)F)=CC=C2S\1 RWQPYMGVFOZQCK-MUXKCCDJSA-N 0.000 claims 1
SHKKROIDZLUCDA-RMORIDSASA-N [4-[(z)-[6-[(2,6-difluorophenyl)methylsulfonyl]-3-oxo-4h-1,4-benzothiazin-2-ylidene]methyl]-2-nitrophenyl] acetate Chemical compound C1=C([N+]([O-])=O)C(OC(=O)C)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3F)F)=CC=C2S\1 SHKKROIDZLUCDA-RMORIDSASA-N 0.000 claims 1
JEDFXBNKOMJZTA-KSEXSDGBSA-N [4-[(z)-[6-[(2,6-difluorophenyl)methylsulfonyl]-3-oxo-4h-1,4-benzothiazin-2-ylidene]methyl]phenyl] acetate Chemical compound C1=CC(OC(=O)C)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3F)F)=CC=C2S\1 JEDFXBNKOMJZTA-KSEXSDGBSA-N 0.000 claims 1
QGAYLINYQYFTMC-UHBFCERESA-N [4-[(z)-[6-[(2,6-dimethoxyphenyl)methylsulfonyl]-3-oxo-4h-1,4-benzothiazin-2-ylidene]methyl]-2-nitrophenyl] 4-methylbenzenesulfonate Chemical compound COC1=CC=CC(OC)=C1CS(=O)(=O)C1=CC=C(S\C(=C/C=2C=C(C(OS(=O)(=O)C=3C=CC(C)=CC=3)=CC=2)[N+]([O-])=O)C(=O)N2)C2=C1 QGAYLINYQYFTMC-UHBFCERESA-N 0.000 claims 1
RSBQYLNSIJQBPL-ROTLSHHCSA-N [4-[(z)-[6-[(2,6-dimethoxyphenyl)methylsulfonyl]-3-oxo-4h-1,4-benzothiazin-2-ylidene]methyl]-2-nitrophenyl] acetate Chemical compound COC1=CC=CC(OC)=C1CS(=O)(=O)C1=CC=C(S\C(=C/C=2C=C(C(OC(C)=O)=CC=2)[N+]([O-])=O)C(=O)N2)C2=C1 RSBQYLNSIJQBPL-ROTLSHHCSA-N 0.000 claims 1
DOBXPJINUNWKAX-MXAYSNPKSA-N [4-[(z)-[6-[(2,6-dimethoxyphenyl)methylsulfonyl]-3-oxo-4h-1,4-benzothiazin-2-ylidene]methyl]phenyl] acetate Chemical compound COC1=CC=CC(OC)=C1CS(=O)(=O)C1=CC=C(S\C(=C/C=2C=CC(OC(C)=O)=CC=2)C(=O)N2)C2=C1 DOBXPJINUNWKAX-MXAYSNPKSA-N 0.000 claims 1
QCSCZBBIFWRKSW-UHBFCERESA-N [4-[(z)-[6-[(2,6-dimethylphenyl)methylsulfonyl]-3-oxo-4h-1,4-benzothiazin-2-ylidene]methyl]-2-nitrophenyl] 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OC(C(=C1)[N+]([O-])=O)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3C)C)=CC=C2S\1 QCSCZBBIFWRKSW-UHBFCERESA-N 0.000 claims 1
XZLKUABZVJTNHV-ROTLSHHCSA-N [4-[(z)-[6-[(2,6-dimethylphenyl)methylsulfonyl]-3-oxo-4h-1,4-benzothiazin-2-ylidene]methyl]-2-nitrophenyl] acetate Chemical compound C1=C([N+]([O-])=O)C(OC(=O)C)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3C)C)=CC=C2S\1 XZLKUABZVJTNHV-ROTLSHHCSA-N 0.000 claims 1
CISSJZSQRKOMFK-MXAYSNPKSA-N [4-[(z)-[6-[(2,6-dimethylphenyl)methylsulfonyl]-3-oxo-4h-1,4-benzothiazin-2-ylidene]methyl]phenyl] acetate Chemical compound C1=CC(OC(=O)C)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3C)C)=CC=C2S\1 CISSJZSQRKOMFK-MXAYSNPKSA-N 0.000 claims 1
125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 1
KGIFCONSEQBSHQ-KSEXSDGBSA-N methyl 2-[4-[(z)-[6-[(2,6-dibromophenyl)methylsulfonyl]-3-oxo-4h-1,4-benzothiazin-2-ylidene]methyl]anilino]acetate Chemical compound C1=CC(NCC(=O)OC)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3Br)Br)=CC=C2S\1 KGIFCONSEQBSHQ-KSEXSDGBSA-N 0.000 claims 1
VVIDOKFOMVNYIL-KSEXSDGBSA-N methyl 2-[4-[(z)-[6-[(2,6-dichlorophenyl)methylsulfonyl]-3-oxo-4h-1,4-benzothiazin-2-ylidene]methyl]anilino]acetate Chemical compound C1=CC(NCC(=O)OC)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3Cl)Cl)=CC=C2S\1 VVIDOKFOMVNYIL-KSEXSDGBSA-N 0.000 claims 1
NJLJHFSMYPESPZ-KSEXSDGBSA-N methyl 2-[4-[(z)-[6-[(2,6-difluorophenyl)methylsulfonyl]-3-oxo-4h-1,4-benzothiazin-2-ylidene]methyl]anilino]acetate Chemical compound C1=CC(NCC(=O)OC)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3F)F)=CC=C2S\1 NJLJHFSMYPESPZ-KSEXSDGBSA-N 0.000 claims 1
PADHBSYXFDUWLP-MXAYSNPKSA-N methyl 2-[4-[(z)-[6-[(2,6-dimethylphenyl)methylsulfonyl]-3-oxo-4h-1,4-benzothiazin-2-ylidene]methyl]anilino]acetate Chemical compound C1=CC(NCC(=O)OC)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3C)C)=CC=C2S\1 PADHBSYXFDUWLP-MXAYSNPKSA-N 0.000 claims 1
DQFZLMRQKHTMEM-YVNNLAQVSA-N methyl 4-[(z)-[6-[(2,6-dibromophenyl)methylsulfonyl]-3-oxo-4h-1,4-benzothiazin-2-ylidene]methyl]-3-nitrobenzoate Chemical compound [O-][N+](=O)C1=CC(C(=O)OC)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3Br)Br)=CC=C2S\1 DQFZLMRQKHTMEM-YVNNLAQVSA-N 0.000 claims 1
GWUKBDGGUYEVIB-JJFYIABZSA-N methyl 4-[(z)-[6-[(2,6-dibromophenyl)methylsulfonyl]-3-oxo-4h-1,4-benzothiazin-2-ylidene]methyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3Br)Br)=CC=C2S\1 GWUKBDGGUYEVIB-JJFYIABZSA-N 0.000 claims 1
VDODKCVOBJIMHD-YVNNLAQVSA-N methyl 4-[(z)-[6-[(2,6-dichlorophenyl)methylsulfonyl]-3-oxo-4h-1,4-benzothiazin-2-ylidene]methyl]-3-nitrobenzoate Chemical compound [O-][N+](=O)C1=CC(C(=O)OC)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3Cl)Cl)=CC=C2S\1 VDODKCVOBJIMHD-YVNNLAQVSA-N 0.000 claims 1
MAMZMBDOUJELRH-JJFYIABZSA-N methyl 4-[(z)-[6-[(2,6-dichlorophenyl)methylsulfonyl]-3-oxo-4h-1,4-benzothiazin-2-ylidene]methyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3Cl)Cl)=CC=C2S\1 MAMZMBDOUJELRH-JJFYIABZSA-N 0.000 claims 1
CPEHGAASBAALRS-YVNNLAQVSA-N methyl 4-[(z)-[6-[(2,6-difluorophenyl)methylsulfonyl]-3-oxo-4h-1,4-benzothiazin-2-ylidene]methyl]-3-nitrobenzoate Chemical compound [O-][N+](=O)C1=CC(C(=O)OC)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3F)F)=CC=C2S\1 CPEHGAASBAALRS-YVNNLAQVSA-N 0.000 claims 1
WFYJDLZEXYHDJW-JJFYIABZSA-N methyl 4-[(z)-[6-[(2,6-difluorophenyl)methylsulfonyl]-3-oxo-4h-1,4-benzothiazin-2-ylidene]methyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1\C=C/1C(=O)NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3F)F)=CC=C2S\1 WFYJDLZEXYHDJW-JJFYIABZSA-N 0.000 claims 1
125000006286 dichlorobenzyl group Chemical group 0.000 description 43
238000006243 chemical reaction Methods 0.000 description 40
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 38
238000005481 NMR spectroscopy Methods 0.000 description 33
239000000203 mixture Substances 0.000 description 33
108090000765 processed proteins & peptides Proteins 0.000 description 26
238000011282 treatment Methods 0.000 description 25
125000006508 2,6-difluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C(F)=C1[H])C([H])([H])* 0.000 description 24
125000005605 benzo group Chemical group 0.000 description 24
239000000460 chlorine Substances 0.000 description 23
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 23
239000003814 drug Substances 0.000 description 19
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 17
102000013702 Cyclin-Dependent Kinase 9 Human genes 0.000 description 17
229940125936 compound 42 Drugs 0.000 description 17
238000002360 preparation method Methods 0.000 description 17
239000007787 solid Substances 0.000 description 15
239000002585 base Substances 0.000 description 14
238000013270 controlled release Methods 0.000 description 13
239000011701 zinc Substances 0.000 description 13
239000002904 solvent Substances 0.000 description 12
125000003545 alkoxy group Chemical group 0.000 description 11
229940079593 drug Drugs 0.000 description 11
125000000524 functional group Chemical group 0.000 description 11
239000013543 active substance Substances 0.000 description 10
238000009472 formulation Methods 0.000 description 10
WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 10
239000000243 solution Substances 0.000 description 10
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 9
125000004432 carbon atom Chemical group C* 0.000 description 9
239000003153 chemical reaction reagent Substances 0.000 description 9
239000000543 intermediate Substances 0.000 description 9
229940049953 phenylacetate Drugs 0.000 description 9
206010025323 Lymphomas Diseases 0.000 description 8
239000004480 active ingredient Substances 0.000 description 8
208000009956 adenocarcinoma Diseases 0.000 description 8
229910052799 carbon Inorganic materials 0.000 description 8
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 8
125000005010 perfluoroalkyl group Chemical group 0.000 description 8
239000000047 product Substances 0.000 description 8
150000001299 aldehydes Chemical class 0.000 description 7
230000015572 biosynthetic process Effects 0.000 description 7
230000005764 inhibitory process Effects 0.000 description 7
LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
241000124008 Mammalia Species 0.000 description 6
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
239000002253 acid Substances 0.000 description 6
125000003277 amino group Chemical group 0.000 description 6
239000000427 antigen Substances 0.000 description 6
108091007433 antigens Proteins 0.000 description 6
102000036639 antigens Human genes 0.000 description 6
230000001588 bifunctional effect Effects 0.000 description 6
238000001914 filtration Methods 0.000 description 6
239000000499 gel Substances 0.000 description 6
238000002514 liquid chromatography mass spectrum Methods 0.000 description 6
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 6
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
239000002244 precipitate Substances 0.000 description 6
230000002829 reductive effect Effects 0.000 description 6
239000000126 substance Substances 0.000 description 6
239000000758 substrate Substances 0.000 description 6
CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 6
MRCKRGSNLOHYRA-UHFFFAOYSA-N (2-nitrophenyl) acetate Chemical compound CC(=O)OC1=CC=CC=C1[N+]([O-])=O MRCKRGSNLOHYRA-UHFFFAOYSA-N 0.000 description 5
206010039491 Sarcoma Diseases 0.000 description 5
150000001408 amides Chemical group 0.000 description 5
125000004429 atom Chemical group 0.000 description 5
125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 5
230000030833 cell death Effects 0.000 description 5
239000002552 dosage form Substances 0.000 description 5
150000002148 esters Chemical class 0.000 description 5
239000000706 filtrate Substances 0.000 description 5
125000005843 halogen group Chemical group 0.000 description 5
230000003287 optical effect Effects 0.000 description 5
238000007911 parenteral administration Methods 0.000 description 5
NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 5
235000018102 proteins Nutrition 0.000 description 5
102000004169 proteins and genes Human genes 0.000 description 5
108090000623 proteins and genes Proteins 0.000 description 5
230000009467 reduction Effects 0.000 description 5
238000006722 reduction reaction Methods 0.000 description 5
230000010076 replication Effects 0.000 description 5
241000894007 species Species 0.000 description 5
206010041823 squamous cell carcinoma Diseases 0.000 description 5
FBPVUBVZRPURIU-UHFFFAOYSA-N 1-hexylpyrrole-2,5-dione Chemical compound CCCCCCN1C(=O)C=CC1=O FBPVUBVZRPURIU-UHFFFAOYSA-N 0.000 description 4
MJNPHLBKHKJDEF-UHFFFAOYSA-N 2h-1$l^{4},2-benzothiazine 1-oxide Chemical compound C1=CC=C2S(=O)NC=CC2=C1 MJNPHLBKHKJDEF-UHFFFAOYSA-N 0.000 description 4
UIRSLBDCOYTZPH-UHFFFAOYSA-N 4h-1,4-thiazin-3-one Chemical compound O=C1CSC=CN1 UIRSLBDCOYTZPH-UHFFFAOYSA-N 0.000 description 4
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
201000009030 Carcinoma Diseases 0.000 description 4
102100036876 Cyclin-K Human genes 0.000 description 4
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
101000713127 Homo sapiens Cyclin-K Proteins 0.000 description 4
206010024612 Lipoma Diseases 0.000 description 4
101001001642 Xenopus laevis Serine/threonine-protein kinase pim-3 Proteins 0.000 description 4
150000001412 amines Chemical class 0.000 description 4
150000001450 anions Chemical class 0.000 description 4
150000001721 carbon Chemical group 0.000 description 4
238000003818 flash chromatography Methods 0.000 description 4
229910052731 fluorine Inorganic materials 0.000 description 4
125000005842 heteroatom Chemical group 0.000 description 4
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
125000001151 peptidyl group Chemical group 0.000 description 4
229920000642 polymer Polymers 0.000 description 4
IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 4
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
150000003254 radicals Chemical class 0.000 description 4
WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 4
HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 4
238000003756 stirring Methods 0.000 description 4
238000006467 substitution reaction Methods 0.000 description 4
239000000725 suspension Substances 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
125000003396 thiol group Chemical group [H]S* 0.000 description 4
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 3
101150041968 CDC13 gene Proteins 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
201000008808 Fibrosarcoma Diseases 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
208000034578 Multiple myelomas Diseases 0.000 description 3
206010035226 Plasma cell myeloma Diseases 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
206010043276 Teratoma Diseases 0.000 description 3
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
239000007983 Tris buffer Substances 0.000 description 3
125000002252 acyl group Chemical group 0.000 description 3
239000003098 androgen Substances 0.000 description 3
238000003556 assay Methods 0.000 description 3
238000000376 autoradiography Methods 0.000 description 3
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
239000000872 buffer Substances 0.000 description 3
230000003197 catalytic effect Effects 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
229910052801 chlorine Inorganic materials 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000003431 cross linking reagent Substances 0.000 description 3
238000011161 development Methods 0.000 description 3
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
229910000397 disodium phosphate Inorganic materials 0.000 description 3
235000019800 disodium phosphate Nutrition 0.000 description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 3
210000002950 fibroblast Anatomy 0.000 description 3
206010016629 fibroma Diseases 0.000 description 3
239000011737 fluorine Substances 0.000 description 3
239000012634 fragment Substances 0.000 description 3
201000011066 hemangioma Diseases 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
229910052740 iodine Inorganic materials 0.000 description 3
230000000670 limiting effect Effects 0.000 description 3
239000002502 liposome Substances 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
239000011859 microparticle Substances 0.000 description 3
150000007524 organic acids Chemical class 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
239000000843 powder Substances 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 3
238000001953 recrystallisation Methods 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
230000004044 response Effects 0.000 description 3
238000004007 reversed phase HPLC Methods 0.000 description 3
229910052717 sulfur Inorganic materials 0.000 description 3
150000003568 thioethers Chemical class 0.000 description 3
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
SSJXIUAHEKJCMH-PHDIDXHHSA-N (1r,2r)-cyclohexane-1,2-diamine Chemical compound N[C@@H]1CCCC[C@H]1N SSJXIUAHEKJCMH-PHDIDXHHSA-N 0.000 description 2
UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
AASYSXRGODIQGY-UHFFFAOYSA-N 1-[1-(2,5-dioxopyrrol-1-yl)hexyl]pyrrole-2,5-dione Chemical compound O=C1C=CC(=O)N1C(CCCCC)N1C(=O)C=CC1=O AASYSXRGODIQGY-UHFFFAOYSA-N 0.000 description 2
UYOUGRXVHQNLON-UHFFFAOYSA-N 1-[1-(2,5-dioxopyrrolidin-1-yl)hexyl]pyrrolidine-2,5-dione Chemical compound O=C1CCC(=O)N1C(CCCCC)N1C(=O)CCC1=O UYOUGRXVHQNLON-UHFFFAOYSA-N 0.000 description 2
XKQYCEFPFNDDSJ-UHFFFAOYSA-N 1-[3-[2-[(4-azido-2-hydroxybenzoyl)amino]ethyldisulfanyl]propanoyloxy]-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound OC1=CC(N=[N+]=[N-])=CC=C1C(=O)NCCSSCCC(=O)ON1C(=O)C(S(O)(=O)=O)CC1=O XKQYCEFPFNDDSJ-UHFFFAOYSA-N 0.000 description 2
238000005160 1H NMR spectroscopy Methods 0.000 description 2
ARGCQEVBJHPOGB-UHFFFAOYSA-N 2,5-dihydrofuran Chemical compound C1OCC=C1 ARGCQEVBJHPOGB-UHFFFAOYSA-N 0.000 description 2
PDFGFQUSSYSWNI-UHFFFAOYSA-N 2-(bromomethyl)-1,3-dichlorobenzene Chemical compound ClC1=CC=CC(Cl)=C1CBr PDFGFQUSSYSWNI-UHFFFAOYSA-N 0.000 description 2
NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 2
206010001488 Aggression Diseases 0.000 description 2
ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 2
201000003076 Angiosarcoma Diseases 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
102000002435 Cyclin T Human genes 0.000 description 2
108010068106 Cyclin T Proteins 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
208000032612 Glial tumor Diseases 0.000 description 2
206010018338 Glioma Diseases 0.000 description 2
208000002927 Hamartoma Diseases 0.000 description 2
208000001258 Hemangiosarcoma Diseases 0.000 description 2
241000282412 Homo Species 0.000 description 2
241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
208000007766 Kaposi sarcoma Diseases 0.000 description 2
208000018142 Leiomyosarcoma Diseases 0.000 description 2
206010064912 Malignant transformation Diseases 0.000 description 2
208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
239000007832 Na2SO4 Substances 0.000 description 2
UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
201000004404 Neurofibroma Diseases 0.000 description 2
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
108700020796 Oncogene Proteins 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
206010061902 Pancreatic neoplasm Diseases 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 2
208000008383 Wilms tumor Diseases 0.000 description 2
IWXQBLUNERMDDK-UHFFFAOYSA-N [Li].CC1NC(C(NC1C)C)C Chemical compound [Li].CC1NC(C(NC1C)C)C IWXQBLUNERMDDK-UHFFFAOYSA-N 0.000 description 2
WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
239000012346 acetyl chloride Substances 0.000 description 2
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
150000001263 acyl chlorides Chemical class 0.000 description 2
238000005804 alkylation reaction Methods 0.000 description 2
BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
235000012538 ammonium bicarbonate Nutrition 0.000 description 2
239000001099 ammonium carbonate Substances 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
150000001503 aryl iodides Chemical class 0.000 description 2
239000012298 atmosphere Substances 0.000 description 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
239000002775 capsule Substances 0.000 description 2
208000002458 carcinoid tumor Diseases 0.000 description 2
230000022131 cell cycle Effects 0.000 description 2
239000007810 chemical reaction solvent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
238000004440 column chromatography Methods 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
235000018417 cysteine Nutrition 0.000 description 2
238000002784 cytotoxicity assay Methods 0.000 description 2
231100000263 cytotoxicity test Toxicity 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
230000005595 deprotonation Effects 0.000 description 2
238000010537 deprotonation reaction Methods 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
239000000539 dimer Substances 0.000 description 2
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
239000000428 dust Substances 0.000 description 2
239000012039 electrophile Substances 0.000 description 2
125000001153 fluoro group Chemical group F* 0.000 description 2
238000004108 freeze drying Methods 0.000 description 2
125000002541 furyl group Chemical group 0.000 description 2
230000014509 gene expression Effects 0.000 description 2
238000011194 good manufacturing practice Methods 0.000 description 2
229940093915 gynecological organic acid Drugs 0.000 description 2
206010073071 hepatocellular carcinoma Diseases 0.000 description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
239000012535 impurity Substances 0.000 description 2
230000006882 induction of apoptosis Effects 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
230000002147 killing effect Effects 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000036212 malign transformation Effects 0.000 description 2
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
201000001441 melanoma Diseases 0.000 description 2
239000012528 membrane Substances 0.000 description 2
206010027191 meningioma Diseases 0.000 description 2
210000002901 mesenchymal stem cell Anatomy 0.000 description 2
239000004005 microsphere Substances 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
238000002156 mixing Methods 0.000 description 2
239000000178 monomer Substances 0.000 description 2
125000001624 naphthyl group Chemical group 0.000 description 2
208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
201000008968 osteosarcoma Diseases 0.000 description 2
239000007800 oxidant agent Substances 0.000 description 2
230000001590 oxidative effect Effects 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
201000002528 pancreatic cancer Diseases 0.000 description 2
208000008443 pancreatic carcinoma Diseases 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
238000003322 phosphorimaging Methods 0.000 description 2
125000003367 polycyclic group Chemical group 0.000 description 2
229910000027 potassium carbonate Inorganic materials 0.000 description 2
235000015320 potassium carbonate Nutrition 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
238000000746 purification Methods 0.000 description 2
125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 2
125000000168 pyrrolyl group Chemical group 0.000 description 2
238000006476 reductive cyclization reaction Methods 0.000 description 2
125000006413 ring segment Chemical group 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
238000000926 separation method Methods 0.000 description 2
230000019491 signal transduction Effects 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910000104 sodium hydride Inorganic materials 0.000 description 2
229910052938 sodium sulfate Inorganic materials 0.000 description 2
235000011152 sodium sulphate Nutrition 0.000 description 2
JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 2
230000006103 sulfonylation Effects 0.000 description 2
238000005694 sulfonylation reaction Methods 0.000 description 2
239000003826 tablet Substances 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
238000004809 thin layer chromatography Methods 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
229910000404 tripotassium phosphate Inorganic materials 0.000 description 2
235000019798 tripotassium phosphate Nutrition 0.000 description 2
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
238000010626 work up procedure Methods 0.000 description 2
BQWBEDSJTMWJAE-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[(2-iodoacetyl)amino]benzoate Chemical compound C1=CC(NC(=O)CI)=CC=C1C(=O)ON1C(=O)CCC1=O BQWBEDSJTMWJAE-UHFFFAOYSA-N 0.000 description 1
PMJWDPGOWBRILU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[4-(2,5-dioxopyrrol-1-yl)phenyl]butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCC(C=C1)=CC=C1N1C(=O)C=CC1=O PMJWDPGOWBRILU-UHFFFAOYSA-N 0.000 description 1
XDIYNQZUNSSENW-UUBOPVPUSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XDIYNQZUNSSENW-UUBOPVPUSA-N 0.000 description 1
125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
VDFVNEFVBPFDSB-UHFFFAOYSA-N 1,3-dioxane Chemical compound C1COCOC1 VDFVNEFVBPFDSB-UHFFFAOYSA-N 0.000 description 1
CZLMRJZAHXYRIX-UHFFFAOYSA-N 1,3-dioxepane Chemical compound C1CCOCOC1 CZLMRJZAHXYRIX-UHFFFAOYSA-N 0.000 description 1
WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
125000005877 1,4-benzodioxanyl group Chemical group 0.000 description 1
FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 1
125000000196 1,4-pentadienyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])=C([H])[H] 0.000 description 1
VILFTWLXLYIEMV-UHFFFAOYSA-N 1,5-difluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC([N+]([O-])=O)=C(F)C=C1F VILFTWLXLYIEMV-UHFFFAOYSA-N 0.000 description 1
OPCMVVKRCLOEDQ-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-(methylamino)pentan-1-one Chemical compound ClC1=CC=C(C=C1)C(C(CCC)NC)=O OPCMVVKRCLOEDQ-UHFFFAOYSA-N 0.000 description 1
DIYPCWKHSODVAP-UHFFFAOYSA-N 1-[3-(2,5-dioxopyrrol-1-yl)benzoyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1=CC=CC(N2C(C=CC2=O)=O)=C1 DIYPCWKHSODVAP-UHFFFAOYSA-N 0.000 description 1
CULQNACJHGHAER-UHFFFAOYSA-N 1-[4-[(2-iodoacetyl)amino]benzoyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1=CC=C(NC(=O)CI)C=C1 CULQNACJHGHAER-UHFFFAOYSA-N 0.000 description 1
QXQAPNSHUJORMC-UHFFFAOYSA-N 1-chloro-4-propylbenzene Chemical compound CCCC1=CC=C(Cl)C=C1 QXQAPNSHUJORMC-UHFFFAOYSA-N 0.000 description 1
PWKNBLFSJAVFAB-UHFFFAOYSA-N 1-fluoro-2-nitrobenzene Chemical class [O-][N+](=O)C1=CC=CC=C1F PWKNBLFSJAVFAB-UHFFFAOYSA-N 0.000 description 1
BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 description 1
ZVAPWJGRRUHKGP-UHFFFAOYSA-N 1h-1,5-benzodiazepine Chemical compound N1C=CC=NC2=CC=CC=C12 ZVAPWJGRRUHKGP-UHFFFAOYSA-N 0.000 description 1
JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
JECYNCQXXKQDJN-UHFFFAOYSA-N 2-(2-methylhexan-2-yloxymethyl)oxirane Chemical compound CCCCC(C)(C)OCC1CO1 JECYNCQXXKQDJN-UHFFFAOYSA-N 0.000 description 1
125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
239000001431 2-methylbenzaldehyde Substances 0.000 description 1
CMWKITSNTDAEDT-UHFFFAOYSA-N 2-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=CC=C1C=O CMWKITSNTDAEDT-UHFFFAOYSA-N 0.000 description 1
SLAMLWHELXOEJZ-UHFFFAOYSA-M 2-nitrobenzoate Chemical compound [O-]C(=O)C1=CC=CC=C1[N+]([O-])=O SLAMLWHELXOEJZ-UHFFFAOYSA-M 0.000 description 1
SLAMLWHELXOEJZ-UHFFFAOYSA-N 2-nitrobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1[N+]([O-])=O SLAMLWHELXOEJZ-UHFFFAOYSA-N 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
GHNLJDPNIAIWOQ-UHFFFAOYSA-N 2h-1$l^{6},2-benzothiazine 1,1-dioxide Chemical class C1=CC=C2S(=O)(=O)NC=CC2=C1 GHNLJDPNIAIWOQ-UHFFFAOYSA-N 0.000 description 1
SQBFMDTYGSMTHZ-UHFFFAOYSA-N 3,4-dihydro-2h-1,4-benzothiazine-7-carboxylic acid Chemical compound N1CCSC2=CC(C(=O)O)=CC=C21 SQBFMDTYGSMTHZ-UHFFFAOYSA-N 0.000 description 1
AWEQJRLHZZUDLE-UHFFFAOYSA-N 3-[3-(2,5-dioxopyrrol-1-yl)benzoyl]-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound C=1C=CC(N2C(C=CC2=O)=O)=CC=1C(=O)C1(S(=O)(=O)O)CC(=O)NC1=O AWEQJRLHZZUDLE-UHFFFAOYSA-N 0.000 description 1
WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
FTAHXMZRJCZXDL-UHFFFAOYSA-N 3-piperideine Chemical compound C1CC=CCN1 FTAHXMZRJCZXDL-UHFFFAOYSA-N 0.000 description 1
YSCNMFDFYJUPEF-OWOJBTEDSA-N 4,4'-diisothiocyano-trans-stilbene-2,2'-disulfonic acid Chemical compound OS(=O)(=O)C1=CC(N=C=S)=CC=C1\C=C\C1=CC=C(N=C=S)C=C1S(O)(=O)=O YSCNMFDFYJUPEF-OWOJBTEDSA-N 0.000 description 1
BAKUAUDFCNFLBX-UHFFFAOYSA-N 4,7-dihydro-1,3-dioxepine Chemical compound C1OCC=CCO1 BAKUAUDFCNFLBX-UHFFFAOYSA-N 0.000 description 1
125000005274 4-hydroxybenzoic acid group Chemical group 0.000 description 1
125000006306 4-iodophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1I 0.000 description 1
QLHLYJHNOCILIT-UHFFFAOYSA-N 4-o-(2,5-dioxopyrrolidin-1-yl) 1-o-[2-[4-(2,5-dioxopyrrolidin-1-yl)oxy-4-oxobutanoyl]oxyethyl] butanedioate Chemical compound O=C1CCC(=O)N1OC(=O)CCC(=O)OCCOC(=O)CCC(=O)ON1C(=O)CCC1=O QLHLYJHNOCILIT-UHFFFAOYSA-N 0.000 description 1
108010013238 70-kDa Ribosomal Protein S6 Kinases Proteins 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
206010001233 Adenoma benign Diseases 0.000 description 1
ZRSNZINYAWTAHE-UHFFFAOYSA-N Anisaldehyde Natural products COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 1
206010003571 Astrocytoma Diseases 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
206010004146 Basal cell carcinoma Diseases 0.000 description 1
206010005949 Bone cancer Diseases 0.000 description 1
206010073106 Bone giant cell tumour malignant Diseases 0.000 description 1
208000018084 Bone neoplasm Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000283707 Capra Species 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
208000005623 Carcinogenesis Diseases 0.000 description 1
208000009458 Carcinoma in Situ Diseases 0.000 description 1
102000005403 Casein Kinases Human genes 0.000 description 1
108010031425 Casein Kinases Proteins 0.000 description 1
102000005483 Cell Cycle Proteins Human genes 0.000 description 1
108010031896 Cell Cycle Proteins Proteins 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
206010008263 Cervical dysplasia Diseases 0.000 description 1
KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
201000005262 Chondroma Diseases 0.000 description 1
208000005243 Chondrosarcoma Diseases 0.000 description 1
201000009047 Chordoma Diseases 0.000 description 1
208000006332 Choriocarcinoma Diseases 0.000 description 1
108010077544 Chromatin Proteins 0.000 description 1
206010048832 Colon adenoma Diseases 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
102000016736 Cyclin Human genes 0.000 description 1
108050006400 Cyclin Proteins 0.000 description 1
102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
230000005778 DNA damage Effects 0.000 description 1
231100000277 DNA damage Toxicity 0.000 description 1
230000004543 DNA replication Effects 0.000 description 1
206010012689 Diabetic retinopathy Diseases 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
208000007033 Dysgerminoma Diseases 0.000 description 1
208000000471 Dysplastic Nevus Syndrome Diseases 0.000 description 1
201000009051 Embryonal Carcinoma Diseases 0.000 description 1
206010014733 Endometrial cancer Diseases 0.000 description 1
206010014759 Endometrial neoplasm Diseases 0.000 description 1
206010014967 Ependymoma Diseases 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
208000006168 Ewing Sarcoma Diseases 0.000 description 1
208000007659 Fibroadenoma Diseases 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
206010053717 Fibrous histiocytoma Diseases 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
102000020897 Formins Human genes 0.000 description 1
108091022623 Formins Proteins 0.000 description 1
DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
208000000527 Germinoma Diseases 0.000 description 1
208000007569 Giant Cell Tumors Diseases 0.000 description 1
201000005409 Gliomatosis cerebri Diseases 0.000 description 1
206010018404 Glucagonoma Diseases 0.000 description 1
206010018691 Granuloma Diseases 0.000 description 1
208000002250 Hematologic Neoplasms Diseases 0.000 description 1
206010019629 Hepatic adenoma Diseases 0.000 description 1
208000005176 Hepatitis C Diseases 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000021519 Hodgkin lymphoma Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
241001272567 Hominoidea Species 0.000 description 1
101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 1
101000650863 Homo sapiens SH2 domain-containing protein 1A Proteins 0.000 description 1
101000652736 Homo sapiens Transgelin Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
208000005045 Interdigitating dendritic cell sarcoma Diseases 0.000 description 1
208000002260 Keloid Diseases 0.000 description 1
NHTGHBARYWONDQ-JTQLQIEISA-N L-α-methyl-Tyrosine Chemical compound OC(=O)[C@](N)(C)CC1=CC=C(O)C=C1 NHTGHBARYWONDQ-JTQLQIEISA-N 0.000 description 1
208000002404 Liver Cell Adenoma Diseases 0.000 description 1
208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
208000030289 Lymphoproliferative disease Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
208000000172 Medulloblastoma Diseases 0.000 description 1
206010027406 Mesothelioma Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
208000014767 Myeloproliferative disease Diseases 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
201000010133 Oligodendroglioma Diseases 0.000 description 1
102000043276 Oncogene Human genes 0.000 description 1
208000010191 Osteitis Deformans Diseases 0.000 description 1
208000000035 Osteochondroma Diseases 0.000 description 1
102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
208000027067 Paget disease of bone Diseases 0.000 description 1
241001494479 Pecora Species 0.000 description 1
208000007641 Pinealoma Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
108700020978 Proto-Oncogene Proteins 0.000 description 1
102000052575 Proto-Oncogene Human genes 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
201000000582 Retinoblastoma Diseases 0.000 description 1
208000005678 Rhabdomyoma Diseases 0.000 description 1
102100027720 SH2 domain-containing protein 1A Human genes 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Natural products OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
201000010208 Seminoma Diseases 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
208000000097 Sertoli-Leydig cell tumor Diseases 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
102100031013 Transgelin Human genes 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
208000009311 VIPoma Diseases 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
208000033779 X-linked lymphoproliferative disease Diseases 0.000 description 1
206010068348 X-linked lymphoproliferative syndrome Diseases 0.000 description 1
206010048214 Xanthoma Diseases 0.000 description 1
206010048215 Xanthomatosis Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
230000002745 absorbent Effects 0.000 description 1
239000003655 absorption accelerator Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
239000011149 active material Substances 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
208000002718 adenomatoid tumor Diseases 0.000 description 1
208000024447 adrenal gland neoplasm Diseases 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000016571 aggressive behavior Effects 0.000 description 1
208000012761 aggressive behavior Diseases 0.000 description 1
IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
150000001336 alkenes Chemical class 0.000 description 1
125000003342 alkenyl group Chemical group 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
230000004075 alteration Effects 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
230000000954 anitussive effect Effects 0.000 description 1
230000002141 anti-parasite Effects 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
238000011319 anticancer therapy Methods 0.000 description 1
239000003096 antiparasitic agent Substances 0.000 description 1
229940124584 antitussives Drugs 0.000 description 1
230000001640 apoptogenic effect Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
238000006254 arylation reaction Methods 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
230000008901 benefit Effects 0.000 description 1
208000001119 benign fibrous histiocytoma Diseases 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
HUMNYLRZRPPJDN-UHFFFAOYSA-N benzenecarboxaldehyde Natural products O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
FBOSKQVOIHEWAX-UHFFFAOYSA-N benzothiazine Chemical compound C1=CC=C2N=CCSC2=C1 FBOSKQVOIHEWAX-UHFFFAOYSA-N 0.000 description 1
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
235000010290 biphenyl Nutrition 0.000 description 1
239000004305 biphenyl Substances 0.000 description 1
NXVYSVARUKNFNF-UHFFFAOYSA-N bis(2,5-dioxopyrrolidin-1-yl) 2,3-dihydroxybutanedioate Chemical compound O=C1CCC(=O)N1OC(=O)C(O)C(O)C(=O)ON1C(=O)CCC1=O NXVYSVARUKNFNF-UHFFFAOYSA-N 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
201000009480 botryoid rhabdomyosarcoma Diseases 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
201000003149 breast fibroadenoma Diseases 0.000 description 1
208000003362 bronchogenic carcinoma Diseases 0.000 description 1
201000002143 bronchus adenoma Diseases 0.000 description 1
YHASWHZGWUONAO-UHFFFAOYSA-N butanoyl butanoate Chemical compound CCCC(=O)OC(=O)CCC YHASWHZGWUONAO-UHFFFAOYSA-N 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
230000036952 cancer formation Effects 0.000 description 1
230000005907 cancer growth Effects 0.000 description 1
125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
125000004623 carbolinyl group Chemical group 0.000 description 1
150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
125000002843 carboxylic acid group Chemical group 0.000 description 1
229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000025084 cell cycle arrest Effects 0.000 description 1
230000006369 cell cycle progression Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
208000019065 cervical carcinoma Diseases 0.000 description 1
210000003679 cervix uteri Anatomy 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
125000000068 chlorophenyl group Chemical group 0.000 description 1
VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
229960002023 chloroprocaine Drugs 0.000 description 1
208000006990 cholangiocarcinoma Diseases 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
201000005217 chondroblastoma Diseases 0.000 description 1
210000003483 chromatin Anatomy 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
208000009060 clear cell adenocarcinoma Diseases 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
238000006482 condensation reaction Methods 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
239000013078 crystal Substances 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
201000010305 cutaneous fibrous histiocytoma Diseases 0.000 description 1
208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
150000001913 cyanates Chemical class 0.000 description 1
WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 1
125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
230000001672 cytoproliferative effect Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
239000002274 desiccant Substances 0.000 description 1
238000013461 design Methods 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
229940043237 diethanolamine Drugs 0.000 description 1
125000006287 difluorobenzyl group Chemical group 0.000 description 1
JIVGSHFYXPRRSZ-UHFFFAOYSA-N dimethoxybenzaldehyde Natural products COC1=CC=CC(C=O)=C1OC JIVGSHFYXPRRSZ-UHFFFAOYSA-N 0.000 description 1
PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
238000004821 distillation Methods 0.000 description 1
ZWIBGKZDAWNIFC-UHFFFAOYSA-N disuccinimidyl suberate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O ZWIBGKZDAWNIFC-UHFFFAOYSA-N 0.000 description 1
GRWZHXKQBITJKP-UHFFFAOYSA-L dithionite(2-) Chemical compound [O-]S(=O)S([O-])=O GRWZHXKQBITJKP-UHFFFAOYSA-L 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
201000009409 embryonal rhabdomyosarcoma Diseases 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
201000003914 endometrial carcinoma Diseases 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
PVBRSNZAOAJRKO-UHFFFAOYSA-N ethyl 2-sulfanylacetate Chemical compound CCOC(=O)CS PVBRSNZAOAJRKO-UHFFFAOYSA-N 0.000 description 1
DLDBPSIPZKTQJE-UHFFFAOYSA-N ethyl 3-[(4-carbamoylphenyl)disulfanyl]propanimidothioate;hydrochloride Chemical compound Cl.CCSC(=N)CCSSC1=CC=C(C(N)=O)C=C1 DLDBPSIPZKTQJE-UHFFFAOYSA-N 0.000 description 1
WSYVIAQNTFPTBI-UHFFFAOYSA-N ethyl 3-[2-[(2-methoxyphenoxy)methyl]-1,3-thiazolidin-3-yl]-3-oxopropanoate Chemical compound CCOC(=O)CC(=O)N1CCSC1COC1=CC=CC=C1OC WSYVIAQNTFPTBI-UHFFFAOYSA-N 0.000 description 1
229940012017 ethylenediamine Drugs 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
230000003176 fibrotic effect Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000011010 flushing procedure Methods 0.000 description 1
235000013305 food Nutrition 0.000 description 1
DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 description 1
201000000052 gastrinoma Diseases 0.000 description 1
238000007429 general method Methods 0.000 description 1
201000003115 germ cell cancer Diseases 0.000 description 1
208000005017 glioblastoma Diseases 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000012010 growth Effects 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
201000010536 head and neck cancer Diseases 0.000 description 1
208000014829 head and neck neoplasm Diseases 0.000 description 1
208000024348 heart neoplasm Diseases 0.000 description 1
201000005787 hematologic cancer Diseases 0.000 description 1
230000009033 hematopoietic malignancy Effects 0.000 description 1
208000006359 hepatoblastoma Diseases 0.000 description 1
201000002735 hepatocellular adenoma Diseases 0.000 description 1
231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000003906 humectant Substances 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
230000003463 hyperproliferative effect Effects 0.000 description 1
MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
201000004933 in situ carcinoma Diseases 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
239000005414 inactive ingredient Substances 0.000 description 1
238000011534 incubation Methods 0.000 description 1
125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
239000000411 inducer Substances 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
206010022498 insulinoma Diseases 0.000 description 1
210000002570 interstitial cell Anatomy 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
201000010985 invasive ductal carcinoma Diseases 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
238000006317 isomerization reaction Methods 0.000 description 1
125000005956 isoquinolyl group Chemical group 0.000 description 1
125000001786 isothiazolyl group Chemical group 0.000 description 1
210000001117 keloid Anatomy 0.000 description 1
OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
229960004752 ketorolac Drugs 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
208000022013 kidney Wilms tumor Diseases 0.000 description 1
208000003849 large cell carcinoma Diseases 0.000 description 1
206010024627 liposarcoma Diseases 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
229910003002 lithium salt Inorganic materials 0.000 description 1
159000000002 lithium salts Chemical class 0.000 description 1
208000014018 liver neoplasm Diseases 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
230000001589 lymphoproliferative effect Effects 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
201000004593 malignant giant cell tumor Diseases 0.000 description 1
201000000289 malignant teratoma Diseases 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
238000002483 medication Methods 0.000 description 1
229960003194 meglumine Drugs 0.000 description 1
210000002418 meninge Anatomy 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical group CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
LLAZQXZGAVBLRX-UHFFFAOYSA-N methyl 2,5-dioxopyrrole-1-carboxylate Chemical compound COC(=O)N1C(=O)C=CC1=O LLAZQXZGAVBLRX-UHFFFAOYSA-N 0.000 description 1
MKIJJIMOAABWGF-UHFFFAOYSA-N methyl 2-sulfanylacetate Chemical compound COC(=O)CS MKIJJIMOAABWGF-UHFFFAOYSA-N 0.000 description 1
CZXGXYBOQYQXQD-UHFFFAOYSA-N methyl benzenesulfonate Chemical compound COS(=O)(=O)C1=CC=CC=C1 CZXGXYBOQYQXQD-UHFFFAOYSA-N 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
229950009623 moguisteine Drugs 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
125000002950 monocyclic group Chemical group 0.000 description 1
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
208000010492 mucinous cystadenocarcinoma Diseases 0.000 description 1
208000009091 myxoma Diseases 0.000 description 1
ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
230000009826 neoplastic cell growth Effects 0.000 description 1
201000008026 nephroblastoma Diseases 0.000 description 1
201000011682 nervous system cancer Diseases 0.000 description 1
208000007538 neurilemmoma Diseases 0.000 description 1
208000004649 neutrophil actin dysfunction Diseases 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
125000006501 nitrophenyl group Chemical group 0.000 description 1
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
238000004305 normal phase HPLC Methods 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
230000002246 oncogenic effect Effects 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
208000003388 osteoid osteoma Diseases 0.000 description 1
208000008798 osteoma Diseases 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
210000003101 oviduct Anatomy 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
UHHKSVZZTYJVEG-UHFFFAOYSA-N oxepane Chemical compound C1CCCOCC1 UHHKSVZZTYJVEG-UHFFFAOYSA-N 0.000 description 1
AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
CVJHVJHLJYPOSS-UHFFFAOYSA-N oxolane;zinc Chemical compound [Zn].C1CCOC1 CVJHVJHLJYPOSS-UHFFFAOYSA-N 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
208000021255 pancreatic insulinoma Diseases 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
VATYWCRQDJIRAI-UHFFFAOYSA-N para-aminobenzaldehyde Natural products NC1=CC=C(C=O)C=C1 VATYWCRQDJIRAI-UHFFFAOYSA-N 0.000 description 1
QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
FXLOVSHXALFLKQ-UHFFFAOYSA-N para-methylbenzaldehyde Natural products CC1=CC=C(C=O)C=C1 FXLOVSHXALFLKQ-UHFFFAOYSA-N 0.000 description 1
239000003182 parenteral nutrition solution Substances 0.000 description 1
230000007170 pathology Effects 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical class OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
CTRLRINCMYICJO-UHFFFAOYSA-N phenyl azide Chemical class [N-]=[N+]=NC1=CC=CC=C1 CTRLRINCMYICJO-UHFFFAOYSA-N 0.000 description 1
CRBZVDLXAIFERF-UHFFFAOYSA-N phloroglucinaldehyde trimethyl ether Natural products COC1=CC(OC)=C(C=O)C(OC)=C1 CRBZVDLXAIFERF-UHFFFAOYSA-N 0.000 description 1
235000011007 phosphoric acid Nutrition 0.000 description 1
150000003016 phosphoric acids Chemical class 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
208000024724 pineal body neoplasm Diseases 0.000 description 1
201000004123 pineal gland cancer Diseases 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
238000010837 poor prognosis Methods 0.000 description 1
230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
WYVAMUWZEOHJOQ-UHFFFAOYSA-N propionic anhydride Chemical compound CCC(=O)OC(=O)CC WYVAMUWZEOHJOQ-UHFFFAOYSA-N 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
125000005493 quinolyl group Chemical group 0.000 description 1
125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
230000005855 radiation Effects 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
208000029922 reticulum cell sarcoma Diseases 0.000 description 1
238000004366 reverse phase liquid chromatography Methods 0.000 description 1
201000009410 rhabdomyosarcoma Diseases 0.000 description 1
238000007363 ring formation reaction Methods 0.000 description 1
YHCWFZMYJZOMPQ-UHFFFAOYSA-N s-(3-ethylsulfanyl-3-iminopropyl) ethanethioate;hydrochloride Chemical compound Cl.CCSC(=N)CCSC(C)=O YHCWFZMYJZOMPQ-UHFFFAOYSA-N 0.000 description 1
239000012723 sample buffer Substances 0.000 description 1
206010039667 schwannoma Diseases 0.000 description 1
208000004548 serous cystadenocarcinoma Diseases 0.000 description 1
210000003625 skull Anatomy 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
235000021286 stilbenes Nutrition 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000004654 survival pathway Effects 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
208000001608 teratocarcinoma Diseases 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000012360 testing method Methods 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
125000003831 tetrazolyl group Chemical group 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
XSROQCDVUIHRSI-UHFFFAOYSA-N thietane Chemical compound C1CSC1 XSROQCDVUIHRSI-UHFFFAOYSA-N 0.000 description 1
VOVUARRWDCVURC-UHFFFAOYSA-N thiirane Chemical compound C1CS1 VOVUARRWDCVURC-UHFFFAOYSA-N 0.000 description 1
RFLTVXIFNKGRKQ-UHFFFAOYSA-N thiochromeno[3,2-b][1,4]benzothiazine Chemical class C1=CC=C2SC3=CC4=CC=CC=C4SC3=NC2=C1 RFLTVXIFNKGRKQ-UHFFFAOYSA-N 0.000 description 1
CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 1
150000003573 thiols Chemical group 0.000 description 1
BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000440 toxicity profile Toxicity 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
229910052723 transition metal Inorganic materials 0.000 description 1
206010044412 transitional cell carcinoma Diseases 0.000 description 1
230000001228 trophic effect Effects 0.000 description 1
208000022271 tubular adenoma Diseases 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
210000003708 urethra Anatomy 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
210000001215 vagina Anatomy 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
208000009540 villous adenoma Diseases 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
210000003905 vulva Anatomy 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
150000003751 zinc Chemical class 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/16—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Hematology (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA2836085A 2013-12-05 2013-12-05 2-benzylidene-2h-benzo[b][1,4] thiazin-3(4h)-ones substituees, derives et usage therapeutique de celles-ci Abandoned CA2836085A1 (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA2836085A CA2836085A1 (fr)	2013-12-05	2013-12-05	2-benzylidene-2h-benzo[b][1,4] thiazin-3(4h)-ones substituees, derives et usage therapeutique de celles-ci

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA2836085A CA2836085A1 (fr)	2013-12-05	2013-12-05	2-benzylidene-2h-benzo[b][1,4] thiazin-3(4h)-ones substituees, derives et usage therapeutique de celles-ci

Publications (1)

Publication Number	Publication Date
CA2836085A1 true CA2836085A1 (fr)	2015-06-05

Family

ID=53365506

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2836085A Abandoned CA2836085A1 (fr)	2013-12-05	2013-12-05	2-benzylidene-2h-benzo[b][1,4] thiazin-3(4h)-ones substituees, derives et usage therapeutique de celles-ci

Country Status (1)

Country	Link
CA (1)	CA2836085A1 (fr)

2013
- 2013-12-05 CA CA2836085A patent/CA2836085A1/fr not_active Abandoned

Legal Events

Date	Code	Title	Description
2019-01-16	FZDE	Dead	Effective date: 20181205

Publication	Publication Date	Title
US9242945B2 (en)	2016-01-26	Substituted 2-benzylidene-2H-benzo[b][1,4]thiazin-3(4H)-ones, derivatives thereof, and therapeutic uses thereof
CA2671426A1 (fr)	2008-06-26	Analogues de sulfure, sulfoxyde et sulfone de chalcone utiles dans le traitement du cancer et autres troubles proliferatifs
ES2718637T3 (es)	2019-07-03	Compuestos para el tratamiento del cáncer
JP6307088B2 (ja)	2018-04-04	キナゾリノンおよびイソキノリノン誘導体
KR20240046530A (ko)	2024-04-09	설폰아미드 유도체, 이의 제조 방법 및 이의 의학적 용도
US8293513B2 (en)	2012-10-23	Histone deacetylase inhibitors
JP2020519582A (ja)	2020-07-02	新規なピペリジン−２，６−ジオン誘導体及びその用途
JP5797664B2 (ja)	2015-10-21	置換ピリド［２，３−ｄ］ピリミジン−７（８Ｈ）−オン及びそれらの治療用の使用
US20220169642A1 (en)	2022-06-02	Compounds for the treatment of oncovirus induced cancer and methods of use thereof
CN104039776B (zh)	2016-06-08	苯并呋喃类衍生物、其制备方法及其在医药上的应用
WO2023212599A2 (fr)	2023-11-02	Composés et méthodes pour la dégradation ciblée de récepteurs d'œstrogène
US20090191193A1 (en)	2009-07-30	Aryl Vinyl Sulfides, Sulfones, Sulfoxides and Sulfonamides, Derivatives Thereof and Therapeutic Uses Thereof
CA2527903A1 (fr)	2004-12-23	Imidazo[2,1-b]-1,3,4-thiadiazole sulfoxydes et sulfones
KR20060109871A (ko)	2006-10-23	증식성 질병 치료용 알파, 베타-불포화 설폭시드
CA2836085A1 (fr)	2015-06-05	2-benzylidene-2h-benzo[b][1,4] thiazin-3(4h)-ones substituees, derives et usage therapeutique de celles-ci
AU2013267035A1 (en)	2015-06-25	SUBSTITUTED 2-BENZYLIDENE-2H-BENZO[b][1,4]THIAZIN-3(4H)-ONES, DERIVATIVES THEREOF, AND THERAPEUTIC USES THEREOF
AU2010330863B2 (en)	2014-06-05	Substituted pyrido[2,3-d]pyrimidin-7(8H)-ones and therapeutic uses thereof
WO2019120298A1 (fr)	2019-06-27	Dérivé de n-(2-cyclohexyléthyl)formamide, son procédé de préparation et son utilisation pharmaceutique
CA2646874C (fr)	2016-08-09	Methodes de preparation de composes du type (e)-styrylbenzylsulfone et utilisations connexes dans le traitement de troubles a evolution chronique
US20150065499A1 (en)	2015-03-05	3-AMINOTHIENO[3,2-c]QUINOLINE DERIVATIVES, METHODS OF PREPARATION AND USES
BR122025013774A2 (pt)	2025-09-02	Compostos inibidores da via de sinalização notch, composição farmacêutica compreendendo os mesmos e uso dos referidos compostos
US20040087580A1 (en)	2004-05-06	4-Hydroxy-2H-thieno[2,3-e]-1,2-thiazine-3-carboxamide-1,1-dioxides, process for preparing and pharmaceutical compositions thereof